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Thesis Abstract 
 
Introduction 
Methods to restore atrial fibrillation (AF) to sinus rhythm include catheter 
ablation and electrical cardioversion. Myocardial fibrosis is associated with 
recurrence and may be measurable using circulating biomarkers. Other 
methods include cardiac magnetic resonance (CMR) and electro-anatomical 
mapping. The aims were: 1) Compare biomarkers in AF patients and controls. 
2) Assess biomarker levels at multiple sampling sites. 3) Determine 
associations between methods of fibrosis quantification. 4) Determine their 
predictive value for arrhythmia recurrence. 
 
Methods 
93 AF ablation patients, 79 cardioversion patients, and 40 control patients were 
enrolled. Enzyme-linked immunosorbent assay was used to determine 
peripheral serum levels of galectin-3 (gal-3), type I collagen C terminal peptide 
(ICTP), type III procollagen N terminal peptide (PIIINP), and fibroblast growth 
factor 23 (FGF-23). Additionally, in ablation patients, levels were measured in 
the coronary sinus and both atria. 31 ablation patients underwent CMR. Follow 
up was 12 months. 
 
Results 
ICTP levels were higher in ablation patients than in controls (p=0.007). 
Peripheral ICTP levels were higher than intracardiac levels (p<0.001), and CS 
levels were higher than atrial levels (p<0.001). Peripheral gal-3 levels were 
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higher than left atrial levels (p=0.001). FGF-23 was weakly predictive of AF 
recurrence after cardioversion (HR 1.003 p=0.012). No other biomarkers 
predicted AF recurrence. Low voltage in the left atrium was the only 
independent predictor of AF recurrence, mapped in sinus rhythm (HR 4.323 
p=0.014) or AF (HR 5.195 p=0.046). LV extracellular volume was associated 
with LA pressure (beta 0.49, P=0.008) and coronary sinus ICTP (beta 0.75, 
P<0.001). 
 
Conclusion 
There is no clinically useful predictive effect of the biomarkers in this study.  
Further research into FGF-23 is warranted. Associations between LV 
extracellular volume, ICTP and LA pressure may suggest elevated ventricular 
myocardial turnover of type I collagen in this cohort, and a possible link with 
atrial pathology. 
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1.1 The problem: atrial fibrillation 
 
Atrial fibrillation (AF) is the most common cardiac arrhythmia, with a prevalence 
of 0.7% in 55-59 year olds, rising to 17.8% in those aged 85 years and older 
[1]. It is characterised clinically by apparent loss of sinoatrial node function, 
irregular atrial excitation and propagation and “irregularly irregular” ventricular 
rhythm. Morbidity and mortality are caused by thromboembolism, due to 
thrombus formation secondary to stasis of blood in the atrium (usually the left 
atrial appendage). The arrhythmia can cause debilitating symptoms and a 
reduction in quality of life, due to abnormal ventricular rate and rhythm and loss 
of atrial function, although in some patients it can be asymptomatic [2, 3]. AF 
can be classified clinically into paroxysmal (occurring in self-limiting episodes 
of less than 7 days’ duration), persistent (lasting beyond 7 days but less than a 
year), long-term persistent (more than a year), or permanent (when the decision 
never to restore sinus rhythm has been made) [4]. 
 
The management of AF is detailed in international guidelines [4]. The main aims 
are the reduction of thromboembolic risk and symptom control. After the 
diagnosis is confirmed, clinical scoring tools such as CHA2DS2VASc aid the 
decision to use anticoagulation treatment [5, 6]. It must then be decided 
whether to accept AF as permanent and control ventricular response (rate 
control), or attempt to restore sinus rhythm (rhythm control). Rhythm control is 
generally considered for symptomatic control; although there is some evidence 
to suggest it may reduce mortality and thromboembolism [7, 8]. This decision, 
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therefore, is based on symptomatic burden, patient choice, and the estimated 
chance of success of restoring sinus rhythm. 
 
Rhythm control strategies include pharmacological or electrical cardioversion, 
percutaneous or surgical atrial fibrillation ablation, or a combination thereof, 
along with pharmacological therapy to promote the maintenance of sinus 
rhythm once it has been restored [4]. Surgical ablation is usually carried out as 
an adjunct to cardiac surgery for other another indication, e.g. valve repair or 
coronary artery bypass grafting, but it can be offered as a standalone treatment 
[4].  
 
AF ablation carries risk, takes time, can be uncomfortable, and may require 
multiple procedures. Reliable prediction of which patients will benefit most, 
leading to better patient selection, is therefore highly desirable, in order to 
optimise patient care. Clinical factors favouring rhythm control strategies such 
as ablation include younger age, shorter duration of AF, paroxysmal AF (as 
opposed to persistent), and a structurally normal heart. Inflammatory disorders, 
valvular disease, left atrial dilatation, cardiomyopathy, and obesity are all 
considered clinical predictors of AF recurrence in individual trials. There is no 
single clinical variable or scoring system which predicts long-term success [9]. 
There is, therefore, a need to identify novel parameters to improve selection of 
patients for invasive rhythm control treatment of AF. 
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1.2 Non-pharmacological rhythm control of AF 
1.2.1 Direct current cardioversion (DCCV) 
 
In the 18th century, it was recognised in animal experiments that a second 
application of electrical current could revive animals which had apparently died 
following a first application [10]. Over the following centuries, ventricular 
fibrillation was described, and it was realised that the mechanism of revival in 
such instances was the termination of ventricular fibrillation by the second 
application of current. After a number of animal experiments using alternating 
current in the first half of the 20th century, the first documented medical use of 
electrical current to convert an arrhythmia to sinus rhythm in a human was in 
1947, in a case of ventricular fibrillation during cardiac surgery [10]. 
 
The first successful use of trans-thoracic electrical discharge to terminate an 
arrhythmia other than ventricular fibrillation was in 1959 by Bernard Lown, on a 
patient with ventricular tachycardia that was not responding to drug therapy, 
again using alternating current [11]. Subsequently, Lown worked with Barouh 
Berkovits, a mechanical engineer, to develop a safer cardioverter-defibrillator 
[10]. They accomplished this via a succession of canine experiments, building 
on the prior work of Gurvich in the Soviet Union, in which they identified that a 
single discharge of direct current, synchronised with the R wave, would lead to 
avoidance of application of current during the vulnerable period of the cardiac 
cycle – which could precipitate ventricular fibrillation [10]. The use of direct 
current allowed lower energy with a shorter duration of discharge, reducing the 
risk of injury to thoracic tissue and the myocardium. This led to the first 
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successful treatment of AF with transthoracic application of electrical current in 
1962 [12]. Lown coined the term “cardioversion” to refer to this method of 
converting an arrhythmia other than ventricular fibrillation to sinus rhythm. 
 
In current practice, cardioversion is carried out under general anaesthetic or 
sedation. A defibrillator is attached to the patient via self-adhesive skin patches 
and ECG leads which the device uses to sense the R wave. The operator 
selects the desired energy (Joules) to be delivered during the discharge. Within 
the defibrillator unit a capacitor is charged via the mains or an internal battery. 
At the appropriate time in the cardiac cycle, the stored charge from the 
capacitor is discharged via the adhesive pads, controlled by an inductor. In 
modern defibrillators, the discharge is delivered in a biphasic current waveform. 
This waveform may be altered by the defibrillator, either by changing the 
duration or voltage, in response to the measured impedance through the 
thorax. This approach allows the device to automatically select the optimal 
mode of delivery of the discharge for the individual patient, while reducing the 
risk of tissue injury from unnecessarily high voltage or duration of current 
application. Biphasic waveforms have been shown to be safer and at least as 
effective as monophasic waveforms [10, 13]. 
 
The precise mechanism by which the arrhythmia is terminated is not fully 
understood. The discharge is thought to lead to depolarisation of the entire 
myocardium, preventing perpetuation of fibrillatory or re-entrant depolarisation 
[14]. Once the myocardium is completely depolarised, the sinoatrial node, 
which exhibits inherent automaticity, initiates normal cardiac depolarisation and 
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sinus rhythm ensues. Cardioversion is therefore more successful at restoring 
sustained sinus rhythm in fibrillation and re-entrant arrhythmias than 
arrhythmias caused by automaticity [15]. 
 
Immediate success of cardioversion for AF is relatively high – approximately 
90%. However, recurrence of arrhythmia is common, with between 50% to 80% 
of patients experiencing recurrence within 12 months [16]. The risk of 
complication is about 1% [17]. Complications include skin burns, ventricular 
arrhythmia, or post-cardioversion bradycardia if SA or AV node disease is 
present. The presence of atrial thrombus must be excluded prior to 
cardioversion – either by trans-oesophageal echocardiography or a period of 
therapeutic anticoagulation prior to the procedure. Without this measure, the 
risk of systemic embolism is about 6% [17]. 
 
1.2.2 Percutaneous catheter ablation of atrial fibrillation 
 
In the late 1990s, Haïssaguerre et. al identified that in some atrial fibrillation 
patients, AF was precipitated by ‘focal triggers’, areas of myocardium which 
depolarise in repetitive high-frequency bursts [18]. Such triggers have been 
identified throughout the atria and into the vena cava, but most commonly in 
the pulmonary veins [18]. This appears to be due, at least in part, to the nature 
of the tissue at the junction of the pulmonary veins and the left atrium. During 
embryological development of the circulatory system, the pulmonary veins arise 
from the lungs and grow towards the primitive left atrium, which in turn forms 
‘buds’ that extend towards the approaching veins [19]. The two sets of 
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structures meet and join to form the venous ostia and thus a continuous 
circulatory connection between the lungs and left atrium [20]. Thus, the terminal 
portion of the veins as they approach the heart is a transition zone from venous 
tissue to myocardium with no distinct, binary border between these tissues. 
Such tissue heterogeneity is potentially arrhythmogenic. Conduction tissue has 
been identified within this transition zone, and in animal studies the pulmonary 
veins have been shown to exhibit automaticity and triggered activity [21, 22]. 
 
Abnormal myocardium elsewhere in the atria has been shown to precipitate 
and sustain atrial fibrillation. This is commonly referred to as AF ‘substrate’ and 
will be described in detail later as it is the main focus of this thesis. 
 
The aim of cardiac ablation is to denature normal myocardium in a controlled 
manner, converting it to scar [23]. Scar tissue interrupts propagation of the 
action potential and thus myocardial depolarisation will be blocked by ablated 
tissue. Arrhythmogenic myocardium can either be converted to non-
arrhythmogenic full-thickness scar, or isolated from the rest of the heart. There 
are a number of methods by which this can be accomplished. In this project of 
work, radiofrequency (RF) was used. 
 
Tissue is heated using a steerable intracardiac catheter. This catheter has a 
metallic, conductive tip. This tip, which becomes the cathode in the subsequent 
circuit, is connected to an RF generator by wires that run within the catheter 
lumen. The circuit anode is a self-adhesive dispersal patch or patches secured 
to the patient’s skin, and also connected to the RF generator. These patches 
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give the anode a larger surface area than the cathode. The RF generator is an 
electrical generator that produces medium frequency alternating current in the 
range of 350-500kHz [24]. A potential difference between the catheter tip and 
the skin patch is generated. Current therefore flows from the generator, to the 
ablation catheter tip, through the patient, to the skin patch, and back to the 
generator. Due to the physical size difference between the catheter tip and the 
skin patch, current density is highest in the tissue local to the catheter tip. It is 
in only in this region of a few millimetres from the catheter tip that temperatures 
rise high enough to cause denaturation [24]. 
 
The current causes resistive heating of the tissue immediately local to the 
catheter tip [24]. Resistive heating refers to the temperature rise caused by the 
passage of current through a conductor due to the motion of charge carriers. 
Heat generated in this way is then dissipated away from the tissue/catheter 
interface via conductive heating, whereby the increased oscillation of tissue 
molecules (predominantly water) caused by resistive heating propagates to 
adjacent molecules. Thus, the effects of ablation beyond the first 1-2mm from 
the ablation catheter are due to conductive heating. Once the temperature of 
tissue rises to approximately 50C, irreversible denaturation occurs and action 
potentials can no longer be conducted. Over time, the initial inflammatory 
reaction dissipates, leaving a fibrotic ‘scar’ - or ablation lesion. In order to create 
ablation lesions that penetrate deeper into tissue, the catheter tip can be 
irrigated with saline, which is pumped through the catheter lumen. This allows 
cooling of the catheter tip/tissue interface, which in turn allows a greater extent 
of conductive heating beyond. Without such irrigation, maximum safe 
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temperature is reached in the tissue close to the catheter before adequate 
lesion depth due to conductive heating can be achieved. Irrigation also allows 
ablation in areas with low blood flow, where the cooling effect of the blood is 
less apparent. Ablation systems also measure tissue impedance, which can be 
displayed to the operator. A fall in impedance implies successful ablation of an 
area of tissue [24]. 
 
For cardiac ablation, access to the heart is gained via the circulatory system, 
usually the femoral veins. To access the left atrium, a puncture of the intra-atrial 
septum is therefore required, except in some cases of persistent foramen ovale. 
The procedure is carried out under conscious sedation or general anaesthetic 
[23]. Using fluoroscopy, electro-anatomical mapping (described later), and 
intracardiac electrograms, the ablation catheter tip can be positioned in the 
desired location. To achieve pulmonary vein isolation with RF ablation, two 
point-by-point lesion sets are created in the pulmonary vein antra, encircling 
each pair of vein ostia. This is referred to as wide-area circumferential ablation 
(WACA) and minimises the risk of pulmonary vein stenosis that can occur if the 
veins themselves are ablated [23]. Ablation catheters which measure 
mechanical contact force between catheter tip and tissue are routinely used in 
RF ablation for AF, as this improves lesion formation by allowing the operator 
to ensure the catheter is in good contact with tissue [25]. 
 
Cryo-ablation is another common technique that is used for AF ablation, during 
which a balloon catheter inserted into the pulmonary vein ostium is rapidly 
cooled. This is achieved by the vaporization, within the catheter balloon, of 
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pressurized nitrous oxide which is pumped through the catheter lumen. The 
vaporized nitrous oxide absorbs heat from the tissue and flows back through a 
second channel in the catheter lumen under suction. Intra- and extra-cellular 
water is frozen, resulting in irreversible cell damage and scar. Outcomes are 
similar to radiofrequency ablation [26]. Other less common techniques include 
laser ablation and surgical ablation, however, like cryo-ablation, they were not 
used in the work described in this thesis. 
 
Reported complication rates vary from 0.8-5% [27-29]. Serious complications 
include pericardial bleeding and resultant tamponade, bleeding from other 
sites, stroke, phrenic nerve palsy, pulmonary vein stenosis, and atrio-
oesophageal fistula. 
 
Published success rates of AF ablation vary significantly. In large multi-centre 
studies, freedom from AF is achieved in up to 80% (paroxysmal AF) or 50-60% 
(persistent AF) [9, 30]. Multiple procedures are required in approximately one 
third of patients in order to achieve these success rates. 
 
The most common mechanism of AF recurrence after ablation is re-connection 
of the pulmonary veins. Therefore, much attention is paid to improving PVI 
techniques. However, other important mechanisms of recurrence include re-
entrant arrhythmias related to the ablation lesions themselves, or the presence 
of arrhythmogenic triggers or substrate within the atrial myocardium, which 
would not be treated with pulmonary vein isolation alone. Identification of this 
non-pulmonary vein substrate is the focus of the work described in this thesis. 
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Strategies for modifying or isolating AF substrate vary, and the evidence for 
substrate ablation is mixed. STAR AF II, a large randomised control study 
comparing pulmonary vein isolation (PVI) alone, with linear ablation and 
complex fractionated electrogram (CFAE) ablation in addition to PVI, found no 
benefit to these substrate ablation strategies [30]. The future direction of 
ablation strategies beyond PVI is therefore under debate, and targeted 
substrate ablation based on more detailed pre-procedural and intra-procedural 
assessment of the properties of the atrial myocardium is a current area of 
research interest. 
 
Myocardial fibrosis – the end result of a number of pathological processes – 
has been associated with AF and is a hallmark of AF substrate.[31] Whether 
fibrosis is a cause or effect of AF (or both) has yet to be determined, however 
identification of myocardial fibrosis may help to predict the probability of 
successful ablation. In addition to improved patient selection, such methods of 
identification of fibrosis may also enable spatial targeting of ablation in those 
patients selected for invasive treatment.  
 
Circulating biomarkers may serve as surrogate measures of underlying 
pathological processes that are associated with fibrosis and AF substrate. If 
such a marker, or markers, could be identified and used in conjunction with 
clinical and imaging criteria, patient selection could be improved, leading to 
improved success rates from rhythm control intervention. The ultimate goal is 
to achieve highly reliable prediction of success leading to the ability to give 
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patients reliable freedom from symptoms and, perhaps, a reduction in 
thromboembolism – a desired benefit of AF ablation that has remained elusive.  
 
In the following sections, the association between fibrosis and atrial fibrillation, 
and its potential clinical relevance, will be explored in more detail. 
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1.3 The extracellular matrix, collagen turnover, and fibrosis 
 
Figure 1-1 Fibrosis association with AF. Post mortem left atrial myocardium. A 
- permanent AF (51% fibrosis). B - paroxysmal AF (14% fibrosis). C - no history 
of AF (5% fibrosis). Reproduced under license. Platonov et al. JACC 2011 [32]. 
 
 
In the normal heart, the extra-cellular matrix (ECM) consists predominantly of 
type I and type 3 collagen, with type I comprising approximately 80% of the total 
collagen [33]. ECM provides a structure or ‘skeleton’, to which the cellular 
components of the myocardium (e.g. cardiomyocytes) are anchored. This 
anchoring is achieved via the ECM glycoprotein fibronectin, which binds to the 
cell membrane-spanning protein integrin. Elastin is also integral to the structure 
of the ECM [34]. The arrangement of these proteins confers both tensile 
strength and elasticity, allowing optimal contractility and recoil of 
cardiomyocytes. Interaction between the ECM, fibroblasts, and cardiomyocytes 
has an important role in the detection of myocardial stretch[31]. Normal ECM 
structure and function is required to allow normal cell to cell signalling and 
conduction of the cardiac action potential across the myocardium.  
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In AF substrate however, the mechanisms that control ECM turnover are 
altered. The ECM becomes abnormal, exhibiting inflammatory and fibrotic 
changes [36, 37].  Figure 1-1 illustrates the extent of atrial fibrosis in post-
mortem analysis of atria from patients with different burdens of AF [32]. 
Resected atrial tissue from surgical patients with AF also reveals a higher 
proportion of left atrial collagen compared to non-AF controls [38, 39]. 
Furthermore, there is increased collagen crosslinking in atrial tissue in patients 
with AF [40]. Cellular changes are also apparent, with proliferation of fibroblasts 
and lymphomononuclear infiltration in the atrial myocardium. Fibroblasts 
differentiate into activated myofibroblasts which secrete paracrine factors as 
well as greater levels of extracellular membrane proteins [41, 42]. Fibroblastic 
proliferation in turn appears to cause cardiomyocyte de-differentiation into an 
embryonic muscle cell type [43]. Cardiomyocyte structure and function across 
the atrial myocardium becomes heterogenous, with varying levels of 
hypertrophy, necrosis, apoptosis and proliferation. This heterogeneity in both 
the cellular and extra-cellular components of the myocardium has been shown 
in animal models to provide a substrate for AF initiation and perpetuation by 
interrupting normal conduction and intercellular signalling [44, 45]. 
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1.4 Conduction in the fibrotic atrium  
 
The mechanisms by which fibrosis causes arrhythmias are not yet fully 
understood, but abnormalities that have been described are represented in 
figure 1-2. 
 
Figure 1-2. Conduction abnormalities in fibrotic myocardium. Reproduced with 
permission. Begg et al. Int J Cardiol 2016. 
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1.4.1 Extracellular changes 
 
Figure 1-3 Histological classification of myocardial fibrosis. Sirius red stain. Red 
areas show collagen. Reproduced under license. De Jong et al. J Cardiovasc 
Pharma 2011 
 
 
The architecture of fibrotic myocardial tissue can vary, and the type of structural 
change can have an impact on conduction [46, 47]. Myocardial fibrosis can be 
classified into four different patterns based on histological appearance, as 
demonstrated in figure 1-3 [45]. ‘Interstitial’ and ‘patchy’ types of fibrosis, which 
are both characterised by the presence of long strands of collagenous material, 
are potential AF substrates. The collagen strands form abnormal insulating 
septa between bundles of cardiomyocytes (perimysial fibrosis) as well as 
increasing the physical distance between individual cardiomyocytes 
(endomysial fibrosis) [48]. Such extracellular structural alterations appear to be 
progressive and associated with the duration of AF; for example, in animal 
studies, greater levels of endomysial and perimysial fibrosis, along with more 
complex, heterogenous conduction changes develop in long – term AF when 
compared with AF of shorter duration [49]. 
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In a persistent AF goat model, this pattern of altered ECM has been shown to 
cause increased conduction block laterally across myocytes after extrastimuli, 
but not longitudinally, resulting in exaggeration of normal anisotropy to a 
pathological extent [49]. 
 
Reduction in conduction velocity, along with the presence of lines of conduction 
block and areas of local activation block, have also been shown via optical 
mapping of resected left atrial appendages from human patients, obtained 
during thorascopic surgery for AF [51]. In the ventricle these changes, causing 
exaggerated differences in lateral and longitudinal conduction velocity, are 
associated with arrhythmia [51]. In a small but interesting study, such 
anisotropy and non-uniform conduction delay due to fibrosis was demonstrated 
in the explanted ventricles of severe heart failure patients after transplant. 
These patients had experienced high rates of ventricular arrhythmia prior to 
transplant [46]. Could the same abnormalities, when present in the atrium, be 
associated with atrial arrhythmia? 
 
1.4.2 Cellular changes 
 
Cardiomyocytes exhibit marked structural and functional changes in fibrotic 
tissue - they appear to undergo partial de-differentiation to a more primitive cell 
phenotype resembling hibernating ventricular cardiomyocytes, with expression 
of embryological protein types such as α-smooth muscle actin, structural 
changes in titin molecules, and nuclear morphology akin to embryological 
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myocytes [53]. This results in reduced contractility and reduced excitability in 
these cells [43]. 
 
Cellular changes are not limited to cardiomyocytes. Although most of the 
myocardial mass is comprised of cardiomyocytes, the most frequent cell is the 
fibroblast. A striking finding in fibrosis is the proliferation of fibroblasts and their 
differentiation into myofibroblasts, which have been identified in pathological 
human atrial as well as ventricular tissue. The previously mentioned de-
differentiation of cardiomyocytes to a more primitive cell type may be a direct 
result of this proliferation and differentiation of fibroblasts [54]. The interaction 
between these cells and cardiomyocytes has therefore been investigated. 
Fibroblasts have modulating effects on conduction in cardiomyocytes; voltage 
and time-gated ion channels are present in the fibroblast cell membrane and 
the resting membrane potential is different from neighbouring cardiomyocytes 
[55]. Indeed, mechanically induced alterations in fibroblast membrane 
potentials, and the ability to interact with cardiomyocytes, have been identified 
for some time, and it has been postulated that in the normal heart they have a 
role in modulation of cardiomyocyte conduction in response to mechanical 
stretch [56-58]. The role of fibroblasts may, in fact, be implicit to cardiomyocyte 
function; the presence of fibroblasts in culture has been shown to cause 
synchronization of contraction in rat cardiomyocyte strands, and allow 
propagation of depolarization across discontinuous cardiomyocyte tissue – 
albeit with significant conduction delay [59]. An increasing density of 
endogenous myofibroblasts results in a biphasic cardiomyocyte conduction 
velocity response and progressive cardiomyocyte depolarization in cultured 
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animal cardiomyocytes [60-62]. A shortening of the atrial refractory period and 
increased potential for re-entry have been demonstrated [49]. Also, 
spontaneous electrical activity has been observed in myofibroblasts in 
monoculture [62]. Although it does not conclusively follow from these in vitro 
studies that this is a mechanism of arrhythmogenesis, the findings highlight that 
fibroblasts and myofibroblasts are electrically active cells and their proliferation 
is likely to be relevant in causing abnormal conduction. 
 
Mechanical, paracrine and electrical mechanisms may be involved in bringing 
about such abnormal conduction. Thomson et al. showed increased expression 
of cadherin, a calcium-dependent adhesion molecule present in adherens 
junctions, in fibrotic cell culture, demonstrating greater mechanical coupling 
between fibroblasts and cardiomyocytes. Subsequent mechanical uncoupling, 
using the myosin inhibitor blebbistatin, resulted in a significant increase in 
conduction velocity, although this was not seen in the earlier study by Pedrotty 
et al [61, 62]. The use of proteolysis reversed the fibroblast effect on conduction 
velocity, suggesting a possible paracrine mechanism at play. Indeed transfer 
growth factor -1, angiotensin II, vascular endothelial growth factor, tumour 
necrosis factor-A, and endothelin-1 have been postulated as paracrine 
mediators of changes in membrane ion channels [63]. This evidence is not 
conclusive, however it suggests that the interaction between 
fibroblasts/myofibroblasts and cardiomyocytes is likely to be multifactorial. 
 
Normal functional interaction between fibroblasts and cardiomyocytes is 
achieved, at least in part, via gap junctions. Such junctions are formed between 
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trans-membrane protein structures, connexons, by which inter-cellular 
signalling is mediated with corresponding connexons on adjacent cell 
membranes. These structures are expressed by fibroblasts, myofibroblasts, 
and cardiomyocytes [58, 65]. In the 2007 study by Chilton et al, rabbit 
cardiomyocytes and myofibroblasts in co-culture demonstrated intercellular 
transfer of dye specific to gap junction channels. This transfer was reduced by 
the inhibition of gap junctions, suggesting that they are at least partially 
responsible for intercellular communication. Connexons are formed by 
connexin proteins, which can be labelled and used as markers of gap junction 
location with the use of immunofluorescence. In normal atria, Cx 40 and 43 
predominate, and gap junctions are located at the ends of cardiomyocytes, at 
the site of the intercalated disc. Lower levels of Cx 40 are thought be a marker 
of abnormal gap junction function, with reduced cell-to-cell coupling and more 
complex activation patterns seen in AF [66]. In humans, there is conflicting 
evidence as to whether Cx 43 expression is reduced in AF but, moreover, 
connexin expression becomes heterogeneous. This in turn suggests 
disordered gap junction communication, which appears to allow the 
propagation of multiple wavefronts, one of the postulated mechanisms of AF 
initiation and sustainment. The same study demonstrated that, in fibrosis, 
connexin expression is increased along the lateral borders of cardiomyocytes, 
as opposed to at the end of the cells, in the usual site of the intercalated disk 
[66]. Electron microscopy confirmed increased cell-to-cell coupling along the 
lateral borders [66]. Similar ‘lateralization’ of gap junctions was demonstrated 
by Spach et al [48]. 
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Arrhythmogenic ion channel alterations have been well documented in AF, 
although findings often conflict between studies regarding precisely which 
channels are affected, and how [67]. This variation in findings has been 
attributed to the difficulty in standardising clinical studies in terms of the 
aetiology of the AF in studied subjects. Voltage – gated potassium channels 
appear to undergo transcriptional downregulation, although the underlying 
disease process may influence the mechanism of alteration and which 
channels and subunits are affected. There appears to be an upward regulation 
of inward-rectifying potassium channels in AF, demonstrated in a number of 
studies of human tissue, allowing an increase in the inward potassium current. 
Such increases in potassium current have been shown to promote AF. The 
intracellular calcium loading that occurs in response to the repetitive 
depolarisation seen in atrial fibrillation is counteracted by downregulation of 
certain calcium channel subunits (ICaL) but not others (ICaT), as well as 
heterogenous changes in inward-rectifying calcium channels. The alteration in 
calcium channel activity appears to cause (or at least relate to) reduction in 
myocardial contractility. Speculatively, such alterations in contractility may 
affect myocyte/fibroblast interaction which may, in turn, alter ECM synthesis 
and function, and are perhaps a contributory factor in fibrosis – further research 
is required to explore this possibility. 
 
Disordered electrical or resistive coupling between cardiomyocytes, fibroblasts 
and myofibroblasts is associated with fibrosis and AF. An example of this 
disordered coupling was seen when stimulation of myocytes was shown to alter 
intracellular calcium concentrations within the myofibroblast [69]. In 
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computational modelling studies, the arrhythmogenic potential of these cellular 
interactions has been described; increase in the resting membrane potential of 
cardiomyocytes, increased electrotonic loading, the ability of fibroblasts and 
myofibroblasts to act as a current ‘sink’, and reduced excitability of sodium 
channels are potential mechanisms for the observed reduction in conduction 
velocity [70, 71]. Arrhythmogenic phenomena such as automaticity and ectopic 
activity are associated with myofibroblast proliferation, although whether this is 
a cause or a consequence is not clear [62].  
 
How, then, do these microscopic mechanisms translate to regional electrical 
changes in the atrium? To attempt to answer this, researchers have employed 
electrical mapping techniques, either with electrode arrays or with the use of 
optical mapping. In a small study (n=6) of bi-atrial electrophysiological mapping 
in surgical patients with AF, lines of conduction block were noted in the right 
atrium, around which multiple large wavefronts propagated. During high density 
electrode mapping during cardiac surgery on permanent AF patients, multiple 
high frequency repetitive activations were documented in the LA. These were 
at a faster rate on the posterior LA wall than elsewhere (including the right 
atrium), lending weight to the hypothesis that triggers may be present in the LA 
[18, 72]. In an ovine model, the characteristics of induced AF were studied in 
posterior left atrial walls, with or without fibrosis, using optical mapping. The 
dominant activation pattern observed was endocardial breakthrough waves. 
Patches of fibrosis were seen to impair wave propagation, cause fractionation 
of wavefronts, and initiate re-entrant circuits [72]. An earlier human study had 
noted this heterogeneous complexity of wavefronts (also showing an inverse 
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relationship between connexin expression and complexity of activation in 
chronic AF) [66]. Finally, Allessie et al. showed that in AF the predominant 
feature was increased dissociation of longitudinal conduction wavefronts in 
adjacent muscle bundles, due to lines of conduction block between these 
bundles – a pattern which would be expected in the presence of collagenous 
septa present in fibrotic myocardium as previously described. More chaotic 
fusion and collision of wavefronts was seen in acute (induced) AF, perhaps 
suggesting these septa and their effects become more pronounced with longer 
AF duration [74].  
 
AF substrate, therefore, exhibits diverse abnormalities leading to complex 
conduction changes. The in-vivo identification of this AF substrate has been 
attractive to clinicians for some time, hoping that targeting such abnormal 
myocardium therapeutically may improve AF outcomes. 
 
1.5 Identification of fibrosis with electro-anatomical mapping 
 
Electro-anatomical mapping systems are integral to complex ablation 
procedures, as they create a visual representation of cardiac anatomy and 
catheter position, reducing the patient’s exposure to X-ray used for fluoroscopic 
visualisation of the intra-cardiac electrodes. Furthermore, these systems 
display a visual representation of electrical information (voltage and activation 
time) that can be used to diagnose arrhythmias and inform the selection of sites 
to ablate.  
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A number of systems exist, but two are predominant in clinical practice. These 
are the CARTO 3 system (Biosense Webster) and the Ensite system 
(Abbott Laboratories, formerly St. Jude Medical). These systems are used in 
the studies within this thesis and therefore only these systems will be discussed 
further. 
 
1.5.1 CARTO 3 
 
CARTO 3 relies on three orthogonally intersecting magnetic fields generated 
by electromagnetic coils positioned beneath the patient’s thorax. Magnetic 
sensors located in the tip of a specialised catheter are used to measure the 
relative strengths of the generated fields. The strength of a magnetic field at a 
given distance from the coil is inversely proportional to that distance. From this 
data therefore, the position of the catheter can be triangulated in 3 dimensions. 
In order to achieve this however, a fixed positional reference is required. This 
is accomplished using a sensor embedded within an adhesive skin patch, which 
is fixed to an area of the patient’s skin which lies within the magnetic fields. The 
placement of multiple sensors in each catheter tip allows the detection of 
catheter roll, yaw and pitch, which are used to project a visual representation 
of catheter position and orientation on the system display [74].  
 
Catheters without magnetic sensors can also be visualised, using 
measurement of electrical impedance. In order to achieve this, the system uses 
detector patches that are placed on the patient’s skin. The system then emits a 
unique current frequency through the electrodes on a given catheter. The 
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relative strengths of the current emitted at a given frequency, measured at each 
patch, can then be used to triangulate the position of the electrode. As each 
electrode emits a different frequency, the position of multiple electrodes can be 
measured and displayed [74]. 
 
1.5.2 Ensite Velocity 
 
The iteration of Ensite used in the studies within this thesis is Ensite Velocity. 
This system does not use magnetic information, but localises catheters based 
upon transthoracic impedance measured by electrodes on the intra-cardiac 
catheter(s). This is the converse of CARTO 3, where the patches measure the 
current emitted from the electrodes. The three pairs of patches used by Ensite 
Velocity are orthogonally positioned on the patient’s skin. A small current 
(5.6kHz frequency) is generated between each pair of patches. The voltage 
and impedance of the current generated between each pair of patches is then 
measured by catheter electrodes [74]. Using this information, the location of the 
electrodes can be triangulated and displayed. In this case, accurate localisation 
depends upon a reference electrode which must remain in a stable position 
[74]. A catheter placed within the coronary sinus is therefore commonly used 
for this purpose. Transthoracic impedance varies with respiration, and this must 
be compensated by measuring the variation and subsequently using this 
measurement in the localisation calculation. 
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1.5.3 Electro-anatomical mapping in clinical use 
 
Both systems use the positional data acquired by the above methods to create 
a ‘point cloud’ of recorded electrode positions within a three-dimensional 
volume as the catheter is moved with the heart. Using user-modifiable criteria 
including electrogram characteristics, catheter stability, impedance, or 
mechanical tissue contact measurements at each point, the systems can 
determine whether an electrode is in contact with the endocardium. By 
identifying which points represent the endocardium, a representation of the 
surface of the chamber of interest (the LA in this case) can be represented 
visually. Thus, an anatomical map is created. 
 
Furthermore, at each point the system records the electrogram signal, and 
timing relative to a chosen reference electrogram – usually from the CS 
catheter. This electrical data can be represented visually, incorporated into the 
anatomical map as colour. Each point on the map has a colour based on the 
desired information at that point, and the system interpolates colour between 
each point to represent gradients. The data used to create this map 
visualisation is user modifiable. Therefore, when electrogram amplitude at each 
location point is represented, the map is referred to as a ‘voltage map’ with a 
colour scale representing signal amplitude. This allows the operator to identify 
areas of low voltage on the endocardium – as is the case with scar or fibrosis. 
Such voltage maps may, therefore, represent areas where arrhythmogenic 
substrate may be present. 
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When signal timing data is represented, the map is an ‘activation map’ with the 
colour scale representing timing of signal relative to the reference. The moving 
wave of activation can also be represented on the electro-anatomical map – a 
‘propagation map’. These types of maps allow the operator to identify 
endocardial activation patterns and are most useful clinically when re-entrant 
or focal tachycardia is present, and less relevant in atrial fibrillation. 
 
The electro-anatomical map can be annotated manually or automatically. For 
example, when mapping the right atrium an operator may mark points where a 
His bundle potential was noted, in order to avoid subsequent ablation of this 
area, or when mapping the left atrium the operator may mark areas of 
electrogram fractionation for later ablation. Locations where ablation has been 
carried out are annotated – usually automatically. The criteria for annotating 
successful lesion creation are user defined (such as time of ablation, energy 
used, catheter stability, fall in impedance, or indices combining such 
measurements). Such visual representations aid the operator in the creation of 
adequate ablation lesions. 
 
1.5.4 Endocardial low voltage areas 
 
In a 2005 study by Verma et. al, the presence of areas of low voltage identified 
by left atrial electrophysiological mapping was studied [59]. The authors 
recruited 700 patients undergoing first-time AF ablation. Voltage mapping was 
performed in sinus rhythm where possible. Initially this was carried out without 
an electro-anatomic mapping system, using intra-cardiac electrogram 
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information alone, but the authors converted to using CARTO 3 part-way 
through recruitment. Scar was defined as areas of voltage between 0.05mV 
and 0.5mV. They identified scar in 42 patients. At baseline, patients with scar 
were more likely to have persistent AF, larger LA diameter, and lower LV 
ejection fraction, and were significantly more likely to experience recurrence of 
AF after ablation. In multivariable analysis incorporating age, ejection fraction, 
LA diameter, duration of AF, paroxysmal vs non-paroxysmal AF and structural 
heart disease, the presence of such areas was the only predictor of recurrence 
(hazard ratio 3.4, 95% CI 1.3 to 9.4, p=0.01).  
 
In 2009, Park et al. assessed regional LA volume and voltage using endocardial 
mapping and spiral computed tomography imaging. They found that LA voltage 
was inversely related to LA volume, and that regional structural remodelling 
was associated with such low voltage areas, suggesting a link between 
abnormalities of underlying myocardium and low voltage [76, 77]. 
 
Strategies to target these low-voltage areas with ablation have therefore been 
proposed, with authors suggesting ablation of the areas themselves, or 
isolation via ablation of their perimeters. Early studies have suggested benefit, 
however further research and validation is required before such techniques can 
enter routine clinical practice [78-80]. 
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1.5.5 Complex fractionated electrograms 
 
Figure 1-4 Examples of CFAEs. Reproduced under licence. Nademanee et al. 
J Cardiol 2010 
 
 
 
Complex fractionated atrial electrograms (CFAEs) can be observed during 
electrophysiological mapping of the atrial myocardium. These electrograms 
represent variability of conduction direction and velocity. Such conduction 
changes imply heterogeneity of the underlying myocardium, be this anatomical, 
functional, or a combination of both. It has been suggested, therefore, that 
CFAEs may indicate the presence of AF substrate. An association between the 
location of CFAEs and sites of left atrial parasympathetic innervation 
(ganglionic plexi) has also been described, and such sites have been 
postulated as AF triggers. Targeted ablation of CFAEs has therefore been 
carried out clinically, with success demonstrated in case series and single 
centre cohort studies [81, 82]. Problems exist because there is no standard 
definition of CFAE,  and methods used to identify them vary – for example 
manual versus automatic identification during electrophysiological mapping 
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[82]. Furthermore, they have been noted within apparently normal atrial 
myocardium. Recent randomised control trial evidence suggests that clinical 
outcomes are not improved by CFAE ablation in persistent AF, even when 
combined with empirical linear LA ablation [30]. 
 
1.5.6 Focal impulse and rotor modulation 
 
Focal impulse and rotor modulation (FIRM) has been proposed as method to 
isolate or ablate AF substrate and/or triggers. This technique uses 
computational analysis of electrograms to identify and ablate localized sources 
such as rotors (rotational activation around a central point) or focal impulses 
(centrifugal activation from a point of origin), and an early study was positive 
[84]. These phenomena have been demonstrated in experimental models of 
AF, and may be related to the fibrotic tissue and conduction changes already 
described, although evidence for their role in initiating and maintaining human 
AF is lacking [85, 86]. The retraction of a randomized trial demonstrating what 
was thought to be a clinical benefit of FIRM ablation has cast doubt on this 
method [87]. 
 
1.5.7 The future of AF ablation 
 
In the largest randomized controlled trial of AF ablation to date, CABANA AF, 
AF ablation was found not to be superior to pharmacological treatment of the 
arrhythmia, for the composite endpoint of death, disabling stroke, serious 
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bleeding, or cardiac arrest[88]. There was significant crossover between the 
treatment groups, however, and the authors have pointed out that AF ablation 
was in fact superior when the results are subjected to on-treatment analysis, 
rather than intention-to-treat. This methodological approach is a source of 
controversy at present, and the impact of CABANA AF is under debate. 
 
Sub-group analysis of this trial is awaited, however a prior study, CASTLE AF, 
suggested a significant benefit on mortality for AF ablation vs medical treatment 
in patients with left ventricular dysfunction[88]. There may be limited 
generalisability to the heart failure population however, as the inclusion criteria 
were strict (approximately 10% of screened patients were included). 
Furthermore, there are some concerns regarding a high event rate in the control 
group, and a high drop-out rate during follow-up. Further analysis of this trial is 
awaited, but heart failure patients with AF may have more to gain from AF 
ablation than was previously recognised. 
 
Other strategies not assessed in STAR AF II, such as left atrial appendage 
isolation, ganglionic plexus ablation, posterior wall isolation, box isolation of 
fragementation, and aggressive left atrial defragmentation have been 
proposed, yet at this point evidence for safety and efficacy of these techniques 
varies in its strength and conclusions[90-94]. 
Given the current lack of strong evidence for ablation beyond pulmonary vein 
isolation, the identification of those patients with heavily fibrosed atria, and 
therefore conceptually a lower chance of long-term success, may be clinically 
relevant. 
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1.6 Identification of fibrosis with cardiac magnetic resonance 
imaging 
 
Endocardial mapping is performed as part of an invasive procedure, and is 
therefore not helpful in pre-procedural prediction of success or patient 
selection. Cardiac magnetic resonance (CMR) imaging is a non-invasive 
imaging method that can be used to quantify overall atrial burden of fibrosis. 
 
MRI relies upon the behaviour of nuclei, when exposed to a magnetic field. Due 
to its abundance in water in the human body, the most commonly interrogated 
nucleus in clinical MRI is hydrogen. In an MRI scanner, a strong magnetic field 
is applied, aligning the magnetic moments of the protons with the field. Pulsed 
radiofrequency energy is then emitted, causing a change in the alignment of 
the proton molecules relative to the magnetic field, after which they return to 
their original, aligned state. This excitation and return to equilibrium causes a 
changing magnetic flux, which can be converted to electrical energy via a 
receiver coil. Protons return to the state of equilibrium at different rates 
depending on the medium in which they are located, emitting radiofrequency 
energy at differing intensities, therefore contrast between different tissues can 
be detected. The application of magnetic gradients through the tissue allows 
signal localisation in three dimensions via Fourier transform. In CMR, ECG 
gating must be used in order to image the moving heart. Breath holding, or 
respiratory gating, can be used to account for respiratory motion. 
 
 56 
CMR allows acquisition of anatomical and functional images of the heart 
including 3-dimensional delineation of the atria. Additionally, the use of 
gadolinium contrast agents can allow the visualisation of areas of fibrosis. This 
is because the currently used gadolinium contrast agents diffuse freely into the 
extravascular and extracellular space and their distribution volume is therefore 
higher in fibrotic compared with normal tissue. Using the CMR method of Late 
Gadolinium Enhancement (LGE), myocardial fibrosis can be detected and its 
extent can be quantified. LGE is mostly applied to imaging of the ventricular 
myocardium which is thicker and more easily imaged than that of the atria. 
However, in recent years, with technological development and improvement in 
spatial resolution, imaging of the atrial myocardium is becoming feasible. Atrial 
LGE imaging does however rely on accurate segmentation of the left atrium, is 
resource-intensive and only available in specialist centres.  
 
Another emerging CMR method is T1 mapping, which is a technique that has 
been developed for estimation of diffuse LV fibrosis. The potential advantage 
of T1 mapping over LGE imaging is that it is more likely to detect diffuse fibrosis. 
This is because LGE relies on a contrast between normal and fibrosed tissue. 
In a diffuse process, this contrast may not be apparent. ‘T1’ refers to the 
longitudinal relaxation time, or the time taken by protons to return to equilibrium 
after excitation by a radiofrequency pulse (see methods section) [94].  An 
increase in native (i.e. non-contrast) T1 is caused by two principal biological 
factors; oedema or an increase in the interstitial space [96]. Oedema is an acute 
phenomenon most commonly related to infarction or inflammation. An increase 
in the interstitial space, however, is more likely to reflect fibrosis, or infiltration. 
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Contrast-enhanced T1 mapping can be used to calculate the extracellular 
volume fraction of the myocardium, with elevated levels suggesting fibrosis 
[96]. There is some evidence that increased ventricular fibrosis measured in 
this manner may predict outcome after AF ablation [97]. 
 
A number of studies, most notably the DECAAF study by Marrouche et al., have 
shown significant correlation between left atrial fibrosis and ablation outcome, 
and these results are awaiting validation in further research [98-100]. The Utah 
group have proposed a classification of LA fibrosis from stages I (<10% of the 
LA wall) to IV (>30%), with AF recurrence rates after ablation of 15% and 51%, 
respectively. 
 
The use of LGE to guide targeted ablation of discrete areas of fibrosis has not 
yet been studied in depth. One study showed a non-significant trend toward an 
association between gadolinium enhancement and CFAE area [100]. Oakes et 
al. again showed a quantitative relationship between gadolinium enhancement 
and low voltage areas on EP mapping [102]. Further improvement in the spatial 
resolution of CMR may allow further work in this area. Technology to allow 
combination of atrial geometry from CMR and EP mapping in the lab already 
exists, and the comparison of CMR defined fibrosis with low voltage, or other 
electrical markers, may be an approach to individualized, fibrosis-targeted 
ablation. 
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1.7 Predicting the success of treatment with circulating 
biomarkers of fibrosis 
 
Figure 1-5 Schematic representation of fibrosis and collagen turnover. 
Substances in green are measurable in the circulation. Reproduced with 
permission. Begg et al, Int J Cardiol 2016 
 
 
 
 
Figure 1-5 indicates some of the circulating substances that are related to 
fibrosis which therefore may be of use as clinical biomarkers. Studies about the 
use of fibrosis biomarkers for the prediction of rhythm control outcome in AF 
are heterogeneous and generally use small sample sizes. Studies that have 
addressed the question, with regards to cardioversion and percutaneous 
ablation, are summarised in table 1-1.  
 
Increased
collagen
synthesis
Increased PICP,
PINP, PIIICP,
PIIINP release
Inflammation Stretch
Cardiomyocyte hypertrophy,
apoptosis, anistropy, reduced 
CV, conduction block, multiple
wavefronts
Increased collagen volume, turnover and
fibril crosslinking, disordered structure,
collagenous septa
+ –
TGF-b, PDGF,
IGF-1, GH, ET-1+3,
gal-3, CTGF
AT-a,-TGF-b,
BNP
IL-1PG, BNP,
TNF-a
TIMPs
MMPs
(collagenolysis)
ICTP
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There are inherent drawbacks with the use of circulating biomarkers in the 
assessment of disease. Neither atrial nor ventricular fibrosis is specific to AF 
and can be caused by other disease – cardiac or otherwise – and, particularly, 
heart failure. At present, no marker specific to cardiac fibrosis, let alone atrial, 
AF-related fibrosis, has been identified. Due to the potential for confounding 
from multiple co-morbidities, studies have tended to exclude a high number of 
patients with such comorbidities, resulting in study populations that are not 
representative of the AF rhythm control population as a whole, which makes 
the generalizability of the results difficult. In the search for greater specificity, 
two studies have attempted to correlate intracardiac marker levels with 
peripheral levels [103, 104]. In these studies, blood was obtained via 
catheterization of the left atrium and coronary sinus in subsets of the overall 
study population. No difference between intracardiac and peripheral levels was 
found. No large multi-centre trials have assessed the ability to predict rhythm 
outcome with circulating biomarkers of fibrosis, and those studies with 
populations numbering in the hundreds have only identified positive 
associations between these markers and rhythm outcome in smaller 
subgroups. This reduces the significance of the results, and often the lower limit 
of the odds or hazard ratio confidence interval is close to 1. There is also the 
temptation to study large panels of biomarkers in the hope of increasing the 
chance of finding a positive association. This strategy, involving multiple 
dependent variables, increases the risk of a type 1 statistical error due to the 
increased likelihood of such an association occurring by chance. Finally, there 
is a relatively small number of studies in this field, with a diverse range of 
potential markers, which results in individual markers being studied in small 
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numbers of patients. No meta-analyses assessing prognostic benefit have 
been carried out on fibrosis biomarkers. 
 
These problems have therefore led to inconsistent results, and it is difficult to 
draw conclusions about the clinical utility of any single biomarker. Of those 
fibrosis biomarkers studied for their utility in predicting arrhythmia recurrence, 
products of turnover of collagen types I and III, rather than regulatory 
substances, appear most promising. This is, perhaps, due to the predominance 
of these types of collagen in cardiac as opposed to extra-cardiac fibrosis, 
whereas these regulatory substances are ubiquitous. 
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Table 1-1 Studies of  relationship between circulating biomarkers of fibrosis and outcome of cardioversion and percutaneous ablation. 
1st Author Ref Sample 
Fibrosis marker(s) 
Study pop. Controls 
Follow 
up 
(months) 
Comments Predictive of 
recurrence 
Not predictive 
Cardioversion 
Kim [105] Plasma TGF-β 
MMP 9 
 
81 - 13 
Multivariate analysis. Length of follow up 
widely variable. TGF-β predicted DCCV 
failure but not recurrence of AF after 
successful DCCV. 
Kato [106] 
Serum / 
plasma 
MMP 2, 
TIMP 2 
MMP 1, 9 
102 
 
- 28 
Pharmacological cardioversion, DCCV if 
unsuccessful. 
Lombardi [107] 
DNA 
(PCR) 
MMP 1, 3 - 74 - 3 weeks 
Analysis of gene polymorphism. Short 
follow up. 
Kawamura [108] Serum PIIINP - 
142 
 
- 24 
Pharmacological cardioversion, DCCV if 
unsuccessful. Excluded ACEI/ARB and BB. 
Short AF duration. 
Mukherjee [109] Plasma 
MMP 3, 9 
TIMP 4 
MMP 1, 2, 7, 8 
TIMP 1-3 
82 - 
3 
 
Open to type 1 error due to multiple 
markers. Short follow up. 
Kallergis [110] Serum ICTP CICP 
164, 
Normal 
 
- 2 
Information on comorbidities not published. 
Short follow up. Population not 
representative - multiple exclusion criteria 
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Percutaneous ablation 
Kim [111] Serum - 
TGF- β,  MMP 
1,2,9 
TIMP 1 
242 (mixed 
PAF and 
PeAF) 
- 22 
Aimed to show relationship between TGF- 
β1, TIMP 1, and LA remodelling rather than 
arrhythmia recurrence. TGF- β1 was 
related to low LA voltage and high LA 
volume.  TIMP-1 was related to low LA 
voltage. 
Okamura [103] 
Serum. 
25 
samples 
from LA 
or mid 
CS 
MMP 2, CITP TIMP 2 
50 
(Mixed 
PAF/ PeAF/ 
LSPeAF) 
- 14 
AADs stopped at 3 months. MMP 2 
predicted recurrence irrespective of 
PAF/non PAF. 
No diff. between LA/CS and peripheral 
levels. Small sample size. 
Richter [112] 
Serum / 
plasma 
PIIINP, but 
only over 
course of 
follow up 
MMP 9, TGF- β1 
30 
(PAF) 
- 6 
Small sample size. Not aimed at 
determining predictive value of baseline 
levels, but the changes in levels over post-
ablation time course. 
Wu [112] Plasma 
TGF- β1 in 
non-PAF 
- 
200 (mixed 
PAF/non-
PAF) 
- 6 
TGF- β1 predicted recurrence in the 46 
nonPAF patients; relatively small sample 
size for this positive association compared 
to overall number. 95% CI for odds ratio 
1.01-1.22. 
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Kimura [114] Serum MMP 2 
ICTP, PINP, TIMP 
2, TGF- β 
44 
(mixed 
PAF/PeAF) 
- 10 
Multiple markers, open to type 1 error. 
Small sample size. 
Sasaki [115] Serum 
MMP 2, 
TIMP 2 
TGF- β1 
60 
(mixed 
PAF/PeAF) 
- 12 
AADs stopped at 2 months. Aimed at post 
– ablation changes in levels. 
Song [116] Serum 
CTGF in 
non-PAF 
patients 
- 
400 (mixed 
PAF/non-
PAF) 
- 20 
AADs stopped at 3 months. Of 400 
patients, 92 were non-PAF in whom the 
association was found. 95% CI for the 
hazard ratio was 1.074 to 1.436. 
Kornej [103] 
Plasma. 
10 
samples 
from CS 
and LA 
- Gal-3 
105 
(mixed 
PAF/PeAF) 
14 6 
AADs stopped at ablation. Higher levels of 
galectin-3 in AF patients related to higher 
BMI on multivariate analysis. 
Canpolat [116] Plasma - 
TGF- β1 (in 
multivariate 
analysis) 
41 (PAF) - 18 
AADs stopped after 3 months. TGF- β1 
was not independently associated with 
recurrence, but did predict extent of fibrosis 
as assessed by LGE-MRI, which in turn 
predicted AF recurrence. 
Wu [118] Plasma Gal-3 - 
50 (PeAF, 
lone) 
46 17 
AADs stopped 2-3 months after ablation. 
Extensive exclusion criteria. Small sample 
size. 
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Takemoto [119] Serum 
Gal-3 
(measured in 
CS, p=0.049) 
CRP, BNP 
29 PAF, 26 
PeAF 
- 12 
CS gal-3 levels only independent predictor. 
Gal-3 levels higher in PeAF than PAF. AF 
cycle length inversely related to Gal-3. LA 
volume index correlated with Gal-3. 
For abbreviations, see main list. 
1.7.1 Collagen turnover biomarkers 
 
Figure 1-6 Collagen synthesis by the fibroblast (or myofibroblast) 
 
 
As has been discussed, the hallmark of fibrosis is an excess of ECM, the 
principal constituent of which is collagen. Furthermore, collagen is not simply 
laid down in excess – there is an increase in collagen turnover as a whole, 
including degradation. Cleaved products arising from type 1 and 3 collagen are 
suitable for study in this context because, in the heart, these collagen types 
predominate. Understanding of the process involved in the turnover is required 
to determine relevant biomarkers. Figure 1-6 shows a generalised overview of 
procollagen synthesis in the fibroblast (or myofibroblast) and its conversion into 
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collagen in the extracellular space. The maintenance and degradation of the 
collagen matrix is less well understood, however. 
 
Type 3 procollagen amino-terminal peptide (PIIINP) is cleaved, in the 
extracellular space, by procollagen peptidase in the formation of type III 
collagen fibrils. Once cleaved it enters the circulation, where it can be measured 
in blood. The peptide appears to exert no physiological effects or have further 
interaction, until it is excreted into urine[119]. 
 
Once type 1 collagen is synthesized and incorporated into the ECM via the 
processes illustrated in fig 1-6, it undergoes continual modification and 
maturation resulting in pyridinoline crosslink formation between the terminal 
telopeptide domains of one molecule and the helical domain of others. As has 
been discussed, this cross-linking appears to be more pronounced in fibrotic 
tissue. Degradation of the collagen polymers during turnover of the tissue 
results in cleavage of these crosslinked terminal peptides[119]. A proportion of 
these peptides enter the circulation, where they appear to be physiologically 
inert, and are excreted in urine (where they were first measured). In the case 
of type 1 collagen, the relevant molecule is referred to as the cross-linked 
carboxyl-terminal telopeptide. 
 
The precise mechanisms of collagen modification and eventual degradation are 
unclear. Matrix-metalloproteinases (MMPs) appear to be involved, in particular 
MMP-1 and MMP-8, however the molecular triggers, regulatory processes, and 
interactions are yet to be described. Nevertheless, increased levels of 
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circulating CITP, which is measurable in the circulation, do appear to be 
associated with increased rates of type 1 collagen degradation. 
 
Two of the studies reported in table 1 tested for PIIINP; one in DCCV and one 
in ablation, and both were predictive of arrhythmia recurrence (see table 1). 
CITP was also predictive of recurrence in two studies, again one in ablation and 
one in DCCV. CITP was found not to predict recurrence in one further ablation 
study, however this study was small (n = 44) and was open to type I error as a 
very large panel of markers was tested. In surgical patients, PIIINP has been 
shown to predict post-operative AF, even in patients with no known history of 
AF before surgery [120]. 
 
1.7.2 Galectin 3 
 
Galectin-3 (gal-3) is a β-galactoside binding protein of the lectin family. The 
structure of gal-3 is, however, distinct from other galectins. It is a soluble protein 
with a single carbohydrate recognition domain. The unique N-terminal domain 
consists of 110-130 amino acids. Between the N- and C- terminal domains is a 
collagen-like span of around 100 amino acids, which contains an H-domain 
which is cleavable by matrix metalloproteinases 2 and 9. The C-terminal 
domain is the carbohydrate binding site[122]. 
 
Gal-3 can be found throughout the cell and, in pentameric form, free in the 
circulation. Its mechanisms of action are diverse and dependent on whether it 
is intra- or extracellular. Intracellularly it has a predominantly anti-apoptotic 
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effect on regulation of the cell cycle, promoting cell proliferation. Extracellularly 
it has the capacity to bind to cell membranes and extracellular matrix, causing 
cell adhesion and restricting migration and growth. In this instance, its effects 
are predominantly pro-apoptotic. The directly pro-fibrotic effects of gal-3 are not 
clearly defined, however it is thought that it forms lectin-saccharide lattices on 
cell surfaces which entrap transforming growth factor- (TGF-). In turn, this 
causes chemo-attraction and activation of macrophages, as well as stimulating 
production of extracellular matrix by fibroblasts and myofibroblasts. Gal-3 
appears to cause up-regulation and retention of TGF- receptors in the cell 
membranes of these cell types[122]. In cardiac pathology, myofibroblast 
proliferation, fibrogenesis, inflammation, and ventricular remodelling have all 
been associated with galectin-3 involvement[122]. 
 
Gal-3 has been associated with increased risk of AF in the general population, 
although this association was not independent, and higher levels are 
associated with AF of longer duration[123]. In heart failure, gal-3 has been 
found to be sensitive and specific as a marker of disease severity, as well as 
being associated with AF in this patient population[124]. 
 
Galectin-3 has been of interest only recently in the context of AF ablation and 
has not been tested in cardioversion. The studies quoted in table 1 have given 
conflicting results, however further studies are required to elucidate its clinical 
utility. Based on their persistent AF ovine study of upstream gal-3 inhibition, 
which demonstrated a reduction in electrical remodelling and fibrosis by 
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impairment of TGF-ß mediated signalling and myofibroblast activation, 
Takemoto et al. have postulated gal-3 as a possible AF therapeutic target [119]. 
 
1.7.3 Fibroblast growth factor 23 
 
Fibroblast growth factor 23 (FGF-23) is the most recently described member of 
the FGF family. Therefore, understanding of its function is less than complete. 
It is a 251-amino acid peptide that exhibits the common feature of the FGF 
family; a trefoil N-terminal domain comprised of folded -strands and loops. The 
C-terminal domain is unique to FGF-23 and contains a 71 amino-acid 
structure[125]. 
 
It is principally secreted by osteocytes. It was initially identified in its capacity 
as a hormone that acts on the proximal convoluted tubule, possibly via the FGF 
receptor 1c and Klotho co-receptor to increase urinary phosphate excretion via 
suppression of 1-hydroxylase, and, by inhibiting 1,25 dihydroxyvitamin D, 
reduce dietary phosphate absorption[125]. The parathyroid gland appears to 
be another target of FGF-23 action, where the FGF receptor 1c and the Klotho 
co-receptor are also expressed. In murine models there is a strong association 
between FGF-23 and PTH levels[126]. There is also an association between 
FGF-23 levels and hyperparathyroidism in renal disease[125].  
 
Systemic factors that have a role in FGF-23 regulation include phosphate, 
which appears to cause a rise in FGF-23 levels in mice. The level of FGF-23 in 
renal failure appears to be associated with the degree of hyperphosphataemia. 
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1,25 dihydroxyvitamin-D directly stimulates increased osteoblastic synthesis of 
FGF-23[125]. 
 
The majority of research has therefore focussed on its role in phosphate 
homeostasis, bone mineralization, and renal disease. For example, it has been 
associated with heart failure, ventricular hypertrophy, and mortality in patients 
with renal disease, and is implicit in the pathology of hypophosphataemic 
conditions such as certain rickets variants, McCune-Albright syndrome, and 
tumour-induced osteomalacia. Conversely, deletion of the gene encoding for 
FGF23 leads to hyperphosphataemic tumoral calcinosis in mice[125]. 
 
FGF-23 may be expressed in elevated levels in atrial tissues of patients with 
AF [127]. It has been associated with incident AF, increased left ventricular 
mass, heart failure, and cardiovascular death in the general population, as well 
as in chronic kidney disease patients [129]. There is speculation that it has a 
causal role in the association between CKD and AF. There is early evidence 
that FGF-23 may be involved with cardiac fibrosis; FGF-23 has been shown to 
be required for cardiomyocyte proliferation and differentiation in the embryo, 
and this may be relevant given the de-differentiation of cardiomyocytes 
described earlier. There is a strong relationship between FGF-23 and 
myocardial wall tension as measured by higher NT-ProBNP levels, and 
increased myocardial wall tension is a known causative factor for fibrosis, 
possibly through the myocyte to fibroblast intracellular mechanisms already 
described. Vitamin D has been shown to reverse myocardial fibrosis, so the 
inhibitory effects of FGF-23 on vitamin D may negate this protective effect. Most 
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importantly, FGF-23 elevation has been linked with progression of AF. The 
mechanism of this association is unclear and may involve the vitamin D 
pathway, or a more direct fibrogenic effect. Therefore, although not yet 
specifically identified as a direct component of the fibrotic process (such 
research has not taken place), there is evidence of, at least, an indirect link. As 
such, FGF-23 warrants testing in the context of arrhythmia outcomes. 
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2 Aim, hypotheses, and methods 
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2.1 Thesis aim and hypotheses 
 
The aim of the work described in this thesis was to show that atrial fibrosis can 
be practically assessed in the clinical workup of AF patients and that such 
assessment can predict the success of rhythm control treatment for AF. The 
principal aim was to demonstrate that CITP, PIIINP, Gal-3, and FGF-23 (“the 
biomarkers”) are related to left atrial fibrosis and recurrence of AF after 
cardioversion or ablation. To achieve this, and to demonstrate a descriptive 
narrative of the pathophysiology behind this association, the following 
hypotheses were proposed: 
 
1. There is a specific association between the biomarker and the presence 
of AF, therefore serum biomarker levels will be higher in AF patients 
compared with controls. 
 
2. Fibrosis in the left atrium is responsible for the increase in serum 
biomarker levels, therefore left atrial blood will contain a higher 
concentration of the biomarkers than blood from other sites. 
 
3. Fibrosis will be consistently identified across different assessment 
methods, therefore the results quantified with serum biomarkers, electro-
anatomical mapping and CMR will be positively associated. 
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4. LA fibrosis increases the likelihood of atrial arrhythmia recurrence after 
AF ablation, therefore the biomarkers are independently associated with 
success of AF ablation, either individually or collectively. 
 
5. The biomarkers are independently associated with success of DCCV, 
either individually or collectively. 
 
In order to test these hypotheses, the following study groups were proposed 
and submitted (further details in the relevant chapters). 
 
1. Ablation. 
Patients undergoing first-time catheter ablation for AF (paroxysmal, 
persistent or long-standing persistent). After recruitment, these patients 
would undergo pre-procedural echocardiography. During the procedure, 
intra- and extra-cardiac blood would be obtained for later ELISA 
analysis. Left atrial pressure would be measured, and an endocardial 
voltage map of the LA would be generated and stored for later analysis. 
Patients would be followed up for a period of twelve months to screen 
for arrhythmia recurrence. The biomarker levels in these patients would 
be compared with a control population matched for age, gender, and 
comorbidity. 
 
2. CMR 
A group of patients planned for first time AF ablation would undergo a 
pre-procedural CMR scan. This scan would include standard 2D cine 
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imaging of the heart, T1 mapping to assess left ventricular extracellular 
volume, as well as novel 3D imaging to allow reconstruction of the left 
atrium, with LGE analysis to assess LA fibrosis. 
 
3. Cardioversion 
A group of patients undergoing elective direct-current cardioversion 
(DCCV). These patients would undergo pre-procedural 
echocardiography and venepuncture to obtain blood for ELISA analysis. 
They would be assessed at 12 months to screen for arrhythmia 
recurrence. The biomarker levels in these patients would be compared 
with a control population matched for age, gender, and comorbidity. 
 
2.2 Ethical approval 
 
Ethical approval was sought and gained from the NHS Health Research 
Authority Regional Ethics Committee – Leeds West (13/YH/0349). 
 
2.3 Enzyme-linked immunosorbent assay analysis 
2.3.1 General principles 
Enzyme-linked immunosorbent assay (ELISA) is an antibody – dependent 
technique which facilitates the detection of small concentrations of a target 
molecule within a given solute, in this case serum. The method used in this 
study was sandwich ELISA. A polystyrene plate is pre-coated with a ‘capture’ 
antibody, that specifically binds to an antigen on the target molecule. The serum 
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containing this molecule is then added to the plate and incubated for a specific 
time, allowing the capture antibody to bind the target molecule. The plate is 
then washed to remove the serum, leaving only the target molecule and capture 
antibody bound to the plate. Next, a ‘detection’ antibody is added to the plate. 
This detection antibody will specifically bind to the capture antibody/target 
molecule complex. During the manufacturing process, the detection antibody is 
conjugated with horseradish peroxidase (HRP). This is a metalloenzyme found 
in the roots of the horseradish plant, and is not present in mammalian biology. 
When exposed to the correct conditions and substrate, HRP develops a 
coloured derivative of the target molecule. The optical density (adsorbance) of 
this coloured reagent solution is therefore directly proportional to the 
concentration of the target molecule in that solution. 
 
The optical density of the solution is measured using a spectrophotometer – 
light of known intensity and wavelength is transmitted through the solution onto 
a detector. This detector measures the intensity and wavelength of the light 
after it has passed through the solution (incident spectral radiant flux). This is 
then compared to the transmitted spectral radiant flux, and the adsorbance of 
the solution can be calculated. 
 
The adsorbance of solutions containing known concentrations of the target 
molecule are measured (standards). From these known concentrations, a 
standard curve of adsorbance against concentration can be plotted. From this 
curve, the unknown concentrations of target molecule within samples can be 
calculated by measuring the adsorbance of those samples (figure 2-1). 
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2.3.2 Procedure for obtaining serum 
 
For cardioversion and control patients, 8mL of whole blood was drawn from a 
peripheral vein, using standard venepuncture techniques, into 2 x 4mL blood 
tubes containing silica clot activator and serum separator gel (BD Diagnostics, 
Franklin Lakes, NJ, USA). Blood was allowed to stand at room temperature for 
a maximum of 1 hour to allow full coagulation. Samples were spun at 1600g for 
15 minutes in a calibrated swinging bucket centrifuge (Sigma Laborzentrifugen 
GmbH, Germany). Aliquots of the separated serum were transferred to sterile, 
non-pyrogenic Eppendorf tubes and stored at -70oC until analysis. 
 
For ablation patients, 4 x 8mL samples were drawn; one from the femoral vein 
sheath, and 3 intracardiac samples drawn from a long sheath, positioned mid-
chamber in the right atrium, at the coronary sinus ostium, and, after trans-septal 
puncture, the left atrium. Prior to each blood sample aspiration, the contents of 
the femoral or intra-cardiac sheath were aspirated and discarded to ensure no 
contaminants were present in the sample. The sheath was flushed with 
heparinised saline after aspiration. These samples were then processed as 
described above. 
 
2.3.3 ELISA procedure 
 
Samples were thawed at room temperature immediately prior to analysis, so 
underwent only one freeze-thaw cycle. Biomarkers were analysed using 
commercially available enzyme-linked immunosorbent assay (ELISA) kits. Pro-
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collagen type III N-terminal peptide (PIIINP) and galectin-3 (Gal-3) were 
analysed using kits produced by Elabscience (Beijing, China). Type I collagen 
C-terminal telopeptide (ICTP) was analysed using kits produced by Cusabio 
Life Science (Wuhan, China). Such commercially available kits are produced in 
controlled environments and their use reduces the number of steps required 
when performing the assay. This in turn reduces the probability of user error. 
The kits are validated and guaranteed by the manufacturers, and the 
characteristics of the assay are published, such as co-efficients of variation, 
detection levels, linearity, specificity, and precision. These characteristics and 
supporting citations in previous literature were reviewed in order to inform the 
choice of manufacturers [130-132]. 
 
The first step was to determine the appropriate dilution of serum required for 
analysis, as neat serum may have contained too high a concentration of target 
molecule, resulting in saturation of the capture antibody. This was achieved by 
running the assay on samples of differing dilutions of serum, from a number of 
patients (e.g. 1:1, 1:2, 1:4, 1:8 etc.). The adsorbance of each dilution was 
plotted, and the dilution which gave values closest to the centre of the standard 
curve was selected for use in the main assay. For gal-3 a dilution of 1:8 was 
chosen, for the other 3 biomarkers neat serum was chosen. 
 
Kits were processed according to the manufacturer’s instructions. Serum 
concentrations were extrapolated from optical density readings using a 4-
parameter logistic curve derived from the standards, with multiplication by the 
dilution factor in the case of gal-3 (see fig 2-1). In order to correct for 
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adsorbance intrinsic to the polystyrene plate and solution, not related to the 
target molecule, background correction was carried out by measuring the 
adsorbance of wells containing all reagents other than serum in each assay, 
and subtracting this value from the sample values. 
 
As an example, the following steps were followed for the ICTP ELISA: 
 
1. The required plates, reagents and samples were removed from 
refrigeration and allowed to warm to room temperature (18-25C). 
2. Using a micro-pipette, 50l of sample (or standard) was added to each 
well. All standards were tested in duplicate. 
3. 50l of HRP-conjugated detection antibody was added to each well, 
mixing thoroughly. Plates were incubated for 1 hour at 37C. 
4. All liquid was aspirated from each well. Wells were washed 3 times using 
de-ionised water via a multi-channel pipette. At the end of this process 
the plate was inverted and blotted to remove any remaining water. 
5. 100l of the substrate required for the HRP reaction was added to each 
well. The plate was then incubated in the dark at 37C for 15 mins. 
6. 50l of stop solution was added to each well, preventing further colour 
development. 
7. Using a spectrophotometer, the optical density of each well was 
measured and recorded. Transmitted light wavelength was set to 
450nm. 
8. The standard curve was derived, and used to calculate the 
concentrations of the sample wells. 
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A similar process was followed for each biomarker assay, with minor variations 
according to the specific instructions for each kit. 
 
Figure 2-1 Representative example of a 4 parameter logistic standard curve, 
in this case for PIIINP. Red dots indicate adsorbency of standard at known 
concentrations, used to calculate the curve. All standard curves were derived 
by testing in duplicate 
 
 
 
2.3.4 Assay characteristics 
 
The coefficient of variation is a measure of reproducibility of the assay. It is 
calculated by dividing the standard deviation of 10 samples by the mean of 
those samples. The inter- and intra-assay coefficients of variation were as 
published by the manufacturers were <15% for all assays. Lower limits of 
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detection were: ICTP = 25ng/mL, gal-3 = 0.156ng/mL, FGF-23 = 15.625pg/mL, 
PIIINP = 23.438 pg/mL. 
 
2.4 Cardiac magnetic resonance imaging 
 
An overview of the basic principles of MRI have been discussed in the 
introduction section. The aim for this study was to provide standard cine-images 
to assess overall heart structure and function, with additional imaging 
sequences to detect left atrial fibrosis using LGE. Diffuse left ventricular fibrosis 
was assessed using a T1 mapping technique. 
 
CMR scans were carried out on a dedicated cardiovascular 1.5 Tesla Philips 
Ingenia system (Best, Netherlands) in a high volume clinical academic CMR 
unit. Cine imaging in multiple planes was performed, to allow measurement of 
standard LA and LV dimensions. Native T1 maps were acquired (ECG triggered 
5s(3s)3s Modified Look Locker Inversion Recovery (MOLLI) scheme, 
reconstructed voxel size 1.2x1.2x10mm3) on a mid-ventricular short axis slice. 
Fifteen minutes after administration of 0.15mmol/kg intravenous gadolinium 
based contrast agent a post-contrast T1 map was acquired with identical 
planning (4s(2s)3s(2s)2s MOLLI). ECV was calculated using standard methods 
by measuring pre and post contrast T1 in the interventricular septum and blood 
pool[132]. 
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LGE visualization of the LA was obtained via an axial 3D ECG-triggered, free-
breathing inversion recovery turbo gradient echo scan 20 minutes following 
contrast agent administration [134]. Imaging parameters included; repetition 
time (TR) 5.5msec, time to echo (TE) 3.0msec, flip angle 25°, low-high k-space 
ordering, respiratory and ECG-triggering to end atrial diastole, maximum 
120msec acquisition window, respiratory navigator leading, acquired voxel size 
1.3x1.3x4mm3 typically 50 slices per acquisition, reconstructed to 
0.7x0.7x2mm3, Spectral presaturation with inversion recovery (SPIR) fat 
suppression, pixel bandwidth 540Hz, phase-encoding direction antero-
posterior (AP), parallel imaging: Sensitivity encoding P-reduction (AP) factor 2. 
 
Left ventricular endocardial and epicardial contours were manually traced using 
CVI42 software (Circle, Alberta, Canada). Pre- and post-contrast T1 
myocardium and blood pool was analysed on the same software for extra-
cellular volume quantification. A semi-automatic protocol was used to segment 
and quantify left atrial LGE: Using ITK – SNAP software, the segmentation was 
initially constructed automatically using contour edge-attraction [134]. The 
segmentation was then edited manually to ensure accurate endocardial 
apposition. The left atrial appendage was not segmented. The pulmonary veins 
were segmented for 1cm from their ostia. Using software developed in-house 
at King’s College, London, the average signal intensity of a 3-voxel thickness 
shell around the surface of the atrial segmentation was measured. This shell 
therefore encompassed the atrial myocardium. The average signal intensities 
were incorporated into a 3D rendering, and this was analysed using Paraview 
[135]. The mitral valve was not included in this analysis. The number of cells 
 83 
representing scar was divided by the number of cells representing normal 
myocardium to give a percentage myocardial scar value. No standard has been 
identified for identifying the threshold at which cells are identified as scar. 
Fibrosis was defined as tissue with signal intensity greater than one standard 
deviation above blood pool signal intensity, and expressed as a percentage of 
the total LA endocardial area, excluding the left atrial appendage (LAA), the 
mitral valve (MV), and the pulmonary veins (PV). 
 
The 1SD signal intensity cut-off point for the definition of fibrotic myocardium 
was determined using the mitral valve as a comparator, as it is comprised of 
connective tissue, and therefore should have a similar signal intensity to 
completely fibrosed tissue. The mean signal intensity of the mitral valve across 
the whole cohort was 1.75 standard deviations above LA blood pool signal 
intensity (median 1.76, IQR 1.2). The value of one standard deviation was 
therefore chosen, in order to detect partially fibrosed myocardium. Figure 2-2 
illustrates a representative left atrial ‘scarmap’. 
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Figure 2-2 Representative scar map of the LA. Posterior view. In this example, 
a threshold of 1 SD from blood pool = 34% scar 
 
 
 
2.5 Cardioversion 
 
Cardioversion was carried out after a minimum of 4 weeks of therapeutic 
anticoagulation. If the patient was on a vitamin K antagonist, international 
normalised ratio (INR) levels between 1.0 and 2.0 were demonstrated each 
week for 4 weeks. If the patient was on a non-vitamin K antagonist 
anticoagulant, patients were asked if they had missed any doses in the 4 weeks 
prior. A lack of therapeutic anticoagulation was considered a contra-indication 
to cardioversion. Patients were fasted for a minimum of 6 hours prior to the 
procedure. Cardioversion was carried out under general anaesthetic. 
Anaesthetic agents were used according to the preference of the anaesthetist, 
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and included propofol, fentanyl and sevofluorane. No muscle relaxant was 
used. 
 
Cardioversion was administered using an R-Series biphasic defibrillator (Zoll 
Medical). Self-adhesive defibrillation skin patches were attached in an antero-
posterior orientation according to the manufacturer’s instructions. A maximum 
of 3 trans-thoracic biphasic discharges, synchronized to the ECG R wave, were 
delivered via external defibrillator in an escalating energy protocol of 100, 150 
then 200 Joules, until sinus rhythm was restored. Failure to restore sinus 
rhythm after 3 discharges was considered a treatment failure. 
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2.6 Ablation 
 
Procedures were carried out under local anaesthetic with either conscious 
sedation or general anaesthesia. All patients were on therapeutic oral 
anticoagulation. Those on warfarin underwent the ablation without interruption 
to this anticoagulation, with INR between 2.0 and 3.0. Those on a direct factor 
Xa or thrombin inhibitor stopped the anticoagulant 24 hours prior to ablation. In 
non – PAF patients, and PAF patients with risk factors for thrombus formation 
(operator discretion), trans-oesophageal echocardiography was performed to 
exclude intracardiac thrombus. Fluoroscopy was used for imaging in all cases. 
During the procedure, after trans-septal puncture, intravenous heparin was 
administered to maintain an activated clotting time of above 300 seconds. 
 
Venous access was achieved via the left and right femoral veins. A quadripolar 
diagnostic electrophysiology catheter was placed at the right ventricular apex. 
The coronary sinus was selectively engaged with a decapolar catheter. The left 
atrium was accessed via trans-septal puncture with either Brockenbrough or 
Endry’s trans-septal needle, via a fixed-curve Mullins or SL0 braided long 
sheath. Prior to trans-septal puncture, right atrial pressure was measured via 
the transduced sheath. According to the operator’s usual practice, either 2 
separate punctures were performed, or a single puncture was double-wired to 
allow a second, deflectable sheath (Agilis, Abbott) to be introduced into the left 
atrium. The fixed-curve sheath was connected to a transducer to measure left 
atrial pressure. If desired, pulmonary venography was carried out using a 
diagnostic coronary catheter via the fixed-curve sheath. This catheter was then 
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exchanged for a multipolar circular mapping catheter (Lasso, Biosense 
Webster or Advisor, Abbott Laboratories). An irrigated, contact-force 
sensing ablation catheter was introduced to the left atrium via the deflectable 
Agilis sheath (Thermocool SmartTouch, Biosense Webster or Tacticath, 
Abbott Laboratories). 
 
To guide ablation and minimise use of fluoroscopy, left atrial endocardial 
mapping was then carried out using the mapping catheter and 3D mapping 
system – either CARTO 3 (Biosense Webster) or Ensite Velocity (Abbott 
Laboratories). In all patients, a local activation time voltage map was acquired 
simultaneously. 
 
All patients underwent PV isolation via wide area circumferential ablation 
around the PV ostia, according to the operator’s usual technique. PV isolation 
was confirmed by demonstrating entry and exit block, with pacing manoeuvres 
and/or the observation of isolated firing with the pulmonary vein catheter 
advanced into the relevant vein. Further ablation was carried out at operator 
discretion and may have included mitral isthmus line, LA roof line, coronary 
sinus ablation or CFAE ablation. Lines were checked for conduction block using 
pacing manoeuvres or activation mapping. 
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2.7 Electro-anatomical mapping 
 
Left atrial bipolar voltage maps were taken in all patients, irrespective of rhythm, 
after trans-septal puncture using a circular mapping catheter and either CARTO 
3 (Biosense Webster) or Ensite Velocity (Abbott Laboratories) mapping 
systems. The minimum mapping time window for any electrode position was 2 
seconds, in order to account for variation in voltage – particularly for those 
patients in AF during mapping. The minimum number of points collected in any 
single case was 864. Anonymised raw data from these systems was then 
exported according to the manufacturer’s instructions using the data export 
tools included within each system. In collaboration with researchers at the 
Karlsruhe Institute of Technology, the raw data was converted into a 3D map 
that could be manipulated using in-house software [136]. Pulmonary veins, left 
atrial appendage and mitral valve surface were cut away from the patient-
specific atrial anatomies generated during clinical mapping. The resulting shell 
included the voltage data for each anatomical point, and was used to quantify 
the proportion of endocardial surface area which represented fibrotic LA tissue 
based on a voltage value between 0-0.5mV, as a percentage of the overall LA 
endocardial surface. This bipolar voltage range is well established as being 
representative of atrial fibrosis or scar. Figure 2-3 shows a representative 
example. 
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Figure 2-3. Representative example of left atrial voltage map after 
reconstruction (PVs not removed in this image to aid visualisation). Reproduced 
with permission. Begg et.al, Europace, 2016 
 
 
2.8 Echocardiography 
 
Transthoracic echocardiography was performed according to British Society of 
Echocardiography (BSE) guidance. When image quality was sufficient, the LA 
endocardium was traced in the apical long axis and apical 2-chamber views, 
and LA volume calculated using Simpson’s biplane method. LV volumes were 
also calculated in this manner. Standard 2 dimensional and Doppler 
measurements were taken according to the BSE dataset. All scans were 
reviewed, and all measurements taken, by a single assessor with BSE 
accreditation in trans-thoracic echocardiography. 
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2.9 Statistical analysis – general principles 
 
All statistical analysis was performed using SPSS (V22, IBM, Chicago, IL, 
USA). Unless stated otherwise, data are presented as mean ± standard 
deviation, or frequency (percentage). Data were analysed for normality using 
the Shapiro – Wilks test. If data were non-parametric, transformation was 
attempted to achieve normality (log, normal log, reciprocal, or square-root). 
Comparison of means for independent samples was achieved using Student’s 
t test for normal data, and the Mann – Whitney test for non-parametric data. 
Categorical data was compared using the Chi-squared test. A 2 – tailed P value 
of <0.05 was considered statistically significant. This description applies to all 
chapters, but details of further analysis is presented in the relevant chapter. 
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3  Intra-cardiac and peripheral 
levels of biochemical markers 
of fibrosis in patients 
undergoing catheter ablation 
for atrial fibrillation 
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3.1 Introduction 
 
As discussed, there is convincing evidence from animal and human studies that 
myocardial fibrosis of the LA and/or the LV, is involved in the pathophysiology 
of AF. The role of LA fibrosis in particular is of interest as a possible target for 
identification of patients more likely to benefit from rhythm control strategies 
including ablation [98, 138-141]. A number of methods of quantifying such 
fibrosis are available, including imaging techniques such as CMR and 
echocardiography via measurement of integrated backscatter, and minimally 
invasive EP mapping. The role of circulating biochemical markers is also the 
subject of interest for predicting successful rhythm control, and numerous 
potential biomarkers have been studied, with mixed results. 
 
In the context of catheter ablation of AF, the majority of studies assessing 
fibrosis biomarkers have tested peripheral levels. There is an assumption that 
peripheral levels of biomarkers will match intra-cardiac levels. However, this 
assumption has not been conclusively tested, so it is not clear whether intra-
cardiac levels are indeed significantly different from peripheral levels. It is 
difficult to conclude, therefore, that any association between raised fibrosis 
markers and rhythm outcome is necessarily due to cardiac fibrosis, as opposed 
to systemic pathology. 
 
This study was undertaken to compare peripheral levels of four biomarkers of 
fibrosis with intra-cardiac levels, to compare levels in AF patients with matched 
controls, and to compare the levels with left atrial fibrosis, assessed by EP 
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mapping during ablation. The biomarkers chosen, as discussed in chapter 1,  
were PIIINP, ICTP, FGF-23, and gal-3. In order to assess for any AF – specific 
association with these biomarkers, an age- and comorbidity-matched non-AF 
control group was also recruited for comparison. 
 
3.2 Methods 
 
3.2.1 Participants 
 
Written informed consent was obtained from all patients. At a single institution, 
between September 2014 and August 2015, all consecutive patients (n=98) 
undergoing first-time left atrial ablation for paroxysmal, persistent, or long-
standing-persistent AF were screened. Patients were excluded based on the 
criteria in table 3-1, resulting in 95 participants. Two participants subsequently 
decided against ablation and withdrew themselves from the study, resulting in 
a final total of 93 participants in the AF ablation group. 
 
Recruitment of controls followed recruitment of AF patients. Patients attending 
cardiology clinics for non – AF related conditions were screened and selected 
to create a control group with matched overall population values for age, 
gender, left ventricular ejection fraction and comorbidities. Patients were 
excluded from the control group if they had any previously documented AF or 
other sustained arrhythmia of any cause, undiagnosed palpitations, or no 
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documentation of sinus rhythm. Other control group exclusion criteria were the 
same as for the AF group. 
 
Table 3-1 Inclusion and exclusion criteria 
 
3.2.2 Echocardiography 
 
All participants underwent trans-thoracic echocardiography prior to ablation, as 
described in chapter 2. 
 
  
Inclusion criteria Exclusion criteria 
Persistent, long-standing persistent, 
or paroxysmal AF planned for 
catheter ablation 
Previous left atrial ablation 
Age > 18 years Active cancer 
Ability to give informed consent Creatinine >200 mmol/l 
Willing to undergo study procedures 
and receive follow-up telephone 
contact 
Collagen disease (e.g Marfan’s or 
Ehlers-Danlos syndromes) 
 Any systemic inflammatory disease 
(e.g rheumatoid arthritis, 
inflammatory bowel disease). 
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3.2.3 Serum analysis 
 
Whole blood was obtained from the four sites per patient during the ablation 
procedure, but before any tissue ablation occurred, as described in chapter 2.  
 
3.2.4 ELISA 
 
Assays were carried out in accordance with the description in chapter 2. Inter- 
and intra-assay coefficients of variation were <15%.  Lower limits of detection 
were; ICTP = 25ng/mL, gal-3 = 0.156ng/mL, FGF-23 = 15.625pg/mL, PIIINP = 
23.438 pg/mL. 
 
3.2.5 Electrophysiological mapping 
 
Left atrial bipolar electro-anatomical maps were obtained in all patients after 
access was gained to the left atrium, the details of which are described in 
chapter 2. Mapping was carried out irrespective of the patient’s rhythm, and 
cardioversion was not carried out prior to mapping unless the operator felt there 
was a clinical need to do so. 
 
3.2.6 Endpoints 
 
The endpoints for this study were: 
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• A statistically significant association between biomarker levels and 
baseline clinical characteristics of AF ablation patients, including left 
atrial scar assessed by electro-anatomical mapping. 
 
• A statistically significant difference between biomarker levels at different 
sampling sites 
 
• A statistically significant difference between biomarker levels in the AF 
patient cohort and the control cohort. 
 
3.2.7 Power and sample size 
 
To calculate power, it was hypothesized that there would be an increase of 0.5 
standard deviations in the levels of biomarkers in AF patients compared to 
controls. In order to achieve this variance using criteria of 1-β = 0.8 and p<0.05, 
35 patients per group would be required for the comparison part of the study. 
These patients were recruited for both cross-sectional study (described in this 
chapter) and longitudinal study (described in chapter 5), and therefore the 
sample size was based on expected outcome events. In order to achieve 80% 
statistical power to detect the difference in outcome based on biomarker levels, 
using p=0.05 to indicate significance, at least 20 AF recurrence events would 
be required. Therefore, based on local AF recurrence data, target recruitment 
was set at 80 for the ablation group, and 40 for the control group. Over-
recruitment for the AF patients was planned in order to mitigate for any 
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difficulties or lack or reliability with the assay. The final recruitment target was 
therefore 95 
 
3.2.8 Statistical analysis 
 
The basic statistical methods used for analysis are described in chapter 2. For 
analysis in this chapter, for non-parametric data, comparison was made using 
Mann-Whitney test for independent samples, Wilcoxon’s signed rank test for 2 
paired samples, or Friedman’s test for 3 or more paired samples. Friedmans’ 
test indicates a statistically significant difference between any two of the 
analysed groups, so where Friedman’s test was significant, post-hoc Wilcoxon 
tests were carried out to determine where the between-group differences lay, 
with Bonferroni significance correction. Correlations were examined using 
Spearman’s coefficient. For assessment of associations between baseline 
characteristics and biomarker levels, univariable linear regression analysis was 
performed, with mean biomarker levels across the sample sites for each 
participant as the dependent variable. Variables which were associated with a 
significance level of p=0.100 or less were then included in multivariable linear 
regression where the variable data was appropriate for such analysis. Analysis 
was carried out using SPSS version 22 and Minitab version 17. 
 
3.3 Results 
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3.3.1 Baseline characteristics and comparison with controls 
 
Table 3-2 shows the baseline characteristics and comorbidities present within 
the study population, and comparison between characteristics of AF and control 
groups. There was no significant difference between the groups in age, gender, 
LV ejection fraction, or comorbidity. LA volume (but not diameter) was 
significantly higher in the AF group (p=0.007). There was no significant 
difference between levels of PIIINP, FGF-23 or gal-3 between the groups, 
however there was a significantly higher level of ICTP in the AF group 
(p=0.007). 
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Table 3-2 patient characteristics and comparison with controls 
 
Characteristic 
Distribution 
P value AF Group 
n= 93 
Control group 
n = 36 
Age (years) 56.7 ± 11.9 60.7 ± 9.7) 0.073 
BMI (kg/m2) 29.7 ± 5.1 29.3 ± 5.1 0.679 
Paroxysmal AF 63 (67.7) - - 
Time since AF diagnosis (months) 38.9 (59.65) - - 
Female gender 29 (31.2) 11 (30.1) 0.945 
Hypertension 31 (33.3) 17 (47.2) 0.143 
Diabetes Mellitus 9 (9.7) 5 (13.9) 0.490 
Ischaemic Heart Disease 5 (5.4) 4 (11.1) 0.251 
Chronic Kidney Disease 0 (0.0) 0 (0.0) - 
Cerebrovascular disease  5 (5.4) 5 (13.9) 0.105 
CHA2DS2VASc 
Score   
 
0 
1 
2 
3 
4 
5 
41 (44.1) 
17 (18.3) 
22 (23.7) 
10 (10.8) 
2 (2.2) 
1 (1.1) 
- - 
AADs*   
 
Amiodarone 
Flecainide 
Disopyramide 
Propafenone 
Sotalol 
None 
15 (16.1) 
16 (17.2) 
1 (1.1) 
1 (1.1) 
2 (2.2) 
58 (62.4) 
- - 
Rate-limiting 
drugs 
Beta-blocker 
Ca2+ channel blocker 
Digoxin 
No drug 
54 (58.1) 
12 (12.9) 
7 (7.5) 
30 (32.2) 
- - 
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1 drug 
2 drugs 
3 drugs 
56 (60.2) 
6 (6.5) 
1 (1.1) 
Total no. of 
drugs for 
rate/rhythm  
control of AF  
No drug 
1 drug 
2 drugs 
3 drugs 
16 (17.2) 
51 (54.8) 
23 (24.7) 
3 (3.2) 
- - 
LA Volume (mL) 68.0 ± 22.5 56.1 ± 19.4 0.007 
LA Diameter (mm) 40.5 ± 7.0 39.0 ± 5.7 0.263 
Mean LA Pressure (mmHg) 11.0 (9.0) -  
Mean RA Pressure (mmHg) 6.0 (6.0) -  
LV end-diastolic volume (mL) 107.0 ± 29.6 106.9 ± 31.7 0.993 
LV ejection fraction (%) 59.0 ± 7.1 57.3 ± 13.1 0.464 
PIIINP (pg/mL) 60.8 (66.1) 54.6 (59.65) 0.749 
ICTP (ng/mL) 330.1 (324.1) 221.2 (228.6) 0.007 
FGF-23 (pg/mL) 39.7 (29.9) 37.4 (81.1) 0.334 
Gal-3 (ng/mL) 27.7 (43.12) 22.0 (31.3) 0.323 
Values = mean ± standard deviation, median (IQR) or frequency (%) as appropriate. AAD = anti-
arrhythmic drug. BSA = body surface area. *No patients were on >1 AAD 
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Table 3-3 shows regression analysis of relationships between left atrial 
biomarker values and baseline characteristics within the AF ablation group.  
After multivariate analysis, significant associations were found between body-
mass index (BMI) and gal-3 (p<0.001), female gender and gal-3 (p<0.001), LV 
ejection fraction and ICTP (p=0.005), cerebrovascular disease and PIIINP 
(p<0.001), and time since AF diagnosis and PIIINP (p=0.003). Note that for LA 
voltage analysis, values are shown separately for patients in sinus rhythm and 
in AF during EP mapping. There were no associations between biomarker 
levels and LA voltage-defined fibrosis. 
 
3.3.2 Comparison between blood sample sites 
 
Figure 3-1 illustrates the distributions of individual biomarker values at each 
site. No significant difference was found between any of the sites for FGF-23 
or PIIINP. Gal-3 levels were not available for RA and CS sites, but femoral 
levels were significantly higher than left atrial levels (p=0.001). Femoral ICTP 
was higher than LA and RA (p<0.001 for both), and CS ICTP was higher than 
LA (p=0.003) and RA (p<0.001). There was no significant difference between 
the atria, or between femoral and CS levels. 
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Table 3-3 regression analysis 
Characteristic PIIINP ICTP FGF-23 Gal-3 
Beta P Beta p Beta p Beta p 
Age (years) 
0.033 0.838 -0.122 0.306 -0.188 0.339 
0.211 
0.105 
0.059 
0.139 
BMI (kg/m2) 
0.043 0.789 0.112 0.344 
-0.377 
-0.321 
0.048 
 0.063 
0.429 
0.461 
0.000 
 <0.001 
Paroxysmal AF 
0.078 0.625 0.047 0.692 
0.399 
0.210 
0.035 
 0.243 
-0.017 0.877 
Time since AF 
diagnosis 
0.343 
0.389 
0.020 
0.003 
-0.062 0.610 -0.004 0.984 -0.161 0.873 
Female gender 
0.248  
-0.032 
0.114  
0.799 
-0.107 0.370 -0.214 0.274 
0.484 
0.503 
0.000 
 <0.001 
Hypertension 
0.172 0.277 -0.062 0.602 -0.053 0.789 0.095 0.397 
Diabetes Mellitus 
0.018 0.908 
-0.184 
-0.171 
0.120  
0.166 
-0.054 0.787 0.084 0.458 
Ischaemic Heart 
Disease 
0.285 
0.097 
0.068 
 0.449 
0.090 0.450 -0.025 0.898 -0.020 0.861 
Myocardial infarction 
- - - - 
Chronic Kidney Disease 
- - - - 
Cerebrovascular 
disease  
0.313 
 0.511 
0.044 
<0.001 
-0.024 0.838 -0.289 0.136 -0.064 0.567 
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CHA2DS2VASc Score 
0.106 0.468 
-0.197 
-0.037 
0.079 
0.775 
-0.197 0.315 
0.245 
0.354 
0.028 
0.724 
Number of AF drugs 
-0.061 0.677 -0.041 0.720 0.148 0.452 0.045 0.693 
LA Volume / BSA 
(mL/m2) 0.066 0.691 -0.105 0.397 
-0.431 
-0.295 
0.032 
 0.103 
-0.098 0.404 
LA Diameter / BSA 
(mm/m2) 
0.185 0.252 -0.068 0.584 -0.327 0.103 -0.033 0.782 
Mean LA Pressure 
(mmHg) 0.032 0.844 0.067 0.580 -0.302 0.126 
0.209 
0.086 
0.067 
 0.335 
Mean RA Pressure 
(mmHg) 0.031 0.851 -0.087 0.466 
-0.462 
-0.295 
0.015 
0.077 
0.136 0.241 
LV end-diastolic volume 
/ BSA (mL/m2) 
0.102 
 
0.573 
 
0.005 
 
0.967 
 
-0.066 
 
0.771 
 
-0.098 
 
0.404 
 
LV ejection fraction % 
0.140 0.431 
-0.325 
-0.339 
0.001  
0.012 
-0.050 0.827 0.035 0.778 
LA voltage (% 0.2-
0.5mV) (SR n=60) 
0.364 0.080 0.003 0.988 0.104 0.761 0.080 0.652 
LA voltage (% 0.2-
0.5mV) (AF n=33) 
0.171 0.867 -0.409 0.073 -0.576 0.135 0.311 0.131 
 Italics = results of multivariate analysis. Bold italics = significant association after multivariate analysis. 
 
Figure 3-1 Individual values plot of biomarker levels 
 
3.4 Discussion 
 
In this study, the principal findings were that ICTP is higher in AF patients than 
in matched controls, that none of the studied biomarkers were associated with 
LA fibrosis assessed by voltage mapping, and for gal-3 and ICTP, intra-cardiac 
sampling may be necessary to assess their association with intra-cardiac 
processes.  However, intra-cardiac sampling of FGF-23 or PIIINP gives no 
further information over peripheral sampling.  
 
Atrial cardiomyopathy has recently been described expertly by Goette et al. in 
their exhaustive consensus statement [142]. Cardiac fibrosis is a hallmark of 
atrial cardiomyopathy and is characterised by an increase in the turnover of 
extra-cellular matrix. This matrix is principally comprised of type I and type III 
collagen, so PIIINP and ICTP are measurable products of this turnover. Both of 
these biomarkers have shown promise in the prediction of rhythm control 
success [103, 143]. Gal-3 has been shown to have direct and indirect effect on 
cardiac fibrosis and has been studied extensively in the context of heart failure, 
in which it was found to be a relatively sensitive and specific marker of 
ventricular dysfunction, as well as mortality [144-146].  
 
FGF-23, principally studied in the context of its action on phosphate 
homeostasis in kidney disease and heart failure, has been associated with AF, 
increased LV mass, and cardiovascular death [147-149]. Results of studies 
assessing its association with incident AF are mixed [129, 150]. It has been 
shown to be required for cardiomyocyte proliferation and differentiation in early 
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embryonic stages and this may be of interest in AF, as human cardiomyocytes 
in vitro have been shown to de-differentiate to a more primitive cell phenotype 
in cardiac fibrosis [151]. FGF-23 has been associated with increased atrial wall 
tension as manifest by raised NT-ProBNP levels, and it is unclear as to whether 
it has a direct effect on the atrial wall, or increases LA pressure by its effect on 
LV hypertrophy and fibrosis.  
 
3.4.1 Participants and generalizability 
 
This is the largest study that assesses the relationship between peripheral and 
intra-cardiac biochemical markers of fibrosis in an AF ablation population. The 
study population is representative of patients undergoing ablation for AF; 
despite screening of all 98 consecutive patients listed for AF ablation in a 12 
month period, only 3 patients were excluded, and 2 withdrew. The results are 
therefore generalizable to the wider population of AF ablation patients.  
 
Amongst the AF patient population as a whole, such patients represent a 
younger, healthier group with fewer comorbidities, with males being over-
represented. As such, the results may not be as generalizable to AF patient 
groups beyond those suitable for ablation.  As expected, rates of comorbidity 
(e.g. cerebrovascular disease and renal impairment) were low in this 
population, so conclusions drawn about associations between the biomarkers 
and comorbidities should be drawn with caution. 
It should also be noted that there is a large element of scatter amongst the 
biomarker readings as can be seen in figure 3-1 and the inter-quartile ranges 
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of the biomarkers. Despite this, however, statistically significant differences 
between the biomarker distributions could still be determined. 
 
3.4.2 Relationship between intra-cardiac and femoral levels 
 
Peripheral sampling of all four of the biomarkers proportionally represents their 
intra-cardiac levels. In the case of PIIINP and FGF-23, the lack of difference 
between peripheral and intra-cardiac levels suggests that these biomarkers 
may reflect systemic fibrosis (or other non-fibrotic processes in which they are 
involved). In the case of ICTP and gal-3, levels are higher peripherally. 
Therefore, it cannot be concluded that the heart is the main source of these 
substances in the bloodstream. Systemic rather than cardiac pathology may, 
therefore, be the principal driver behind any association between the 
biomarkers and successful treatment of AF. Such findings are in agreement 
with the study by Okumura et al., which showed no difference between intra-
cardiac and femoral levels of their chosen inflammation and extra-cellular 
matrix turnover markers (which included ICTP) in 25 ablation patients [103]. 
 
3.4.3 Intra-cardiac differences 
 
PIIINP and FGF-23 were not significantly different between intra-cardiac sites. 
Therefore, any fibrosis present within the myocardium does not appear to 
contribute to a detectable increase of these compounds in the blood. However, 
ICTP was higher in the CS than either the LA or the RA. This suggests that 
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ICTP enters the bloodstream from the myocardium at detectable levels, 
although, as discussed, this is masked in peripheral blood. This finding does 
not distinguish between ICTP arising from the ventricle or the atrium. 
 
3.4.4 Relationship with baseline characteristics 
 
In this study there is no evidence to support a relationship between the 
biomarkers and simple baseline echocardiographic markers of left atrial 
morphology. Neither is there any relationship with AF classification, 
(paroxysmal vs. non-paroxysmal patients), however PIIINP was associated 
with duration of AF, measured by time since reported clinical diagnosis. PIIINP 
has been shown to have a complex relationship with AF incidence, with mixed 
results regarding its association with AF duration [152]. More work is required 
to understand the role PIIINP may play in relation to the temporal progression 
of the disease. The BMI and gender associations which were encountered with 
gal-3 have been previously described in other patient groups [153, 154]. A 
relationship between ICTP and ventricular function has also been described, to 
a much lesser extent. This study was not designed to examine such an 
association, and as only 5 patients had a reduced LVEF, further studies are 
required. Similarly, although an association between PIIINP and 
cerebrovascular disease was found in this study, this was based on only 5 
patients and should be interpreted with appropriate caution. 
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3.4.5 Relationship with LA voltage data 
 
The presence of low voltage areas within the LA has been shown to be an 
independent predictor of AF recurrence after ablation, and there is evidence 
that these areas of low voltage are associated with fibrosis identified with MRI 
[77, 155]. Voltage criteria for identifying such areas are not universally 
established, however studies have addressed the issue [77, 156]. The definition 
of ‘low voltage’ in this study (<0.5mV) is drawn from this work. Assuming that 
this method is a consistent index of LA fibrosis, the results suggest that levels 
of these four biomarkers are not reflective of atrial fibrosis. For the biomarkers 
where there is some prior evidence of predictive value of arrhythmia recurrence 
(PIIINP, ICTP and gal-3), this may reflect their involvement in fibrosis elsewhere 
in the heart (e.g. the LV), or elsewhere in the body. 
 
3.4.6 Implications 
 
PIIINP and gal-3 levels have been associated with incidence of AF, but their 
use in the prediction of catheter ablation success has yielded mixed results 
[146, 157, 158]. This study may help to explain why this is the case, as it 
suggests that systemic (or at least non-atrial) factors may have the prominent 
role in their presence in the circulation, as evidenced by the lack of difference 
in matched controls. If cardiac fibrosis is the critical component determining 
success in AF ablation, then such markers may have limited use in this role.  
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No studies have addressed the clinical utility of FGF-23 in predicting the 
success of AF ablation, and the findings presented here suggest such utility 
may be limited. On the other hand, ICTP does appear to be involved in local 
cardiac fibrosis and this may help to explain why it has shown more promise. 
In this study, however, we have shown that ICTP does not appear to be 
significantly associated with LA fibrosis. Therefore, it is potentially fibrosis 
elsewhere within the heart, most likely the LV, which the increased CS ICTP 
levels reflect. 
 
3.5 Conclusion 
 
ICTP levels are associated with the presence of AF in comparison with non-AF 
controls. PIIINP levels are associated with AF duration. None of ICTP, PIIINP, 
gal-3 or FGF-23 appear to reflect atrial fibrosis when assessed by voltage 
mapping criteria. Intra-cardiac sampling of FGF-23 or PIIINP gives no further 
information over peripheral sampling. For gal-3 and ICTP, intra-cardiac 
sampling may be necessary to assess their association with intra-cardiac 
processes. 
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4 Circulating biomarkers of 
fibrosis and cardioversion of 
atrial fibrillation 
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4.1 Introduction 
 
Elective direct current cardioversion (DCCV) remains an established treatment 
for symptomatic persistent atrial fibrillation [159]. As discussed, it is immediately 
successful in up to 90% of cases, however more than half of patients will have 
experienced recurrence of AF after one year [160, 161]. Even in anticoagulated 
patients, DCCV carries a small risk (approximately 1%) of arterial 
thromboembolism and stroke [162]. Improved assessment of the likelihood of 
recurrence may aid better patient selection for rhythm control with DCCV, 
reducing the number of patients unnecessarily exposed to this risk. 
 
As discussed in chapter 1, LA fibrosis has been associated with AF and 
recurrence of AF after rhythm control intervention [162]. Clinical methods of 
assessment of this fibrosis include LGE CMR, and invasive electrophysiological 
mapping. Both of these methods have been shown to have predictive value for 
arrhythmia recurrence after percutaneous ablation [77, 98]. However, LGE 
CMR of the LA is technically challenging and not widely available, and EP 
mapping is an invasive test requiring direct access to the left atrium. Neither is 
therefore suitable for assessing the risk of AF recurrence after cardioversion in 
usual clinical practice, and more practical methods are desirable. Such a 
method of assessment for DCCV patients may include the use of circulating 
biomarkers, as discussed in chapter 1. A number of substances involved in 
fibrosis can be measured in peripheral blood and therefore have the potential 
to act as biomarkers.  
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A study was designed to test the hypothesis that the four fibrosis biomarkers 
described in chapter 1 would predict AF recurrence after DCCV. It was also 
hypothesised that these markers would be related to parameters of left atrial 
remodelling assessed by standard echocardiographic measurements, and 
would be higher in AF patients when compared to disease and age-matched 
controls. 
 
4.2 Methods 
 
4.2.1 Participants 
 
All patients recruited gave written informed consent. At a single institution, 
patients due for DCCV for atrial fibrillation were screened between October 
2014 and August 2015. The inclusion criteria were the presence of persistent 
symptomatic AF planned for elective cardioversion, age over 18 years, and the 
ability to give informed consent. Exclusion criteria were the same as the 
previous chapter (see table 3-1). 
 
Participants in the control group were selected from patients attending general 
cardiology clinic for non-arrhythmia related conditions or symptoms. 
Participants were selectively recruited to create a control cohort matched for 
age, gender and comorbidity with the DCCV cohort. Similar exclusion criteria 
were applied, with the presence of any history of AF, other sustained atrial 
arrhythmia, or undiagnosed palpitations additionally. 
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4.2.2 Cardioversion 
 
External electrical cardioversions were carried out under general anaesthetic 
as described in chapter 2.  
 
4.2.3 ELISA 
 
Blood was taken from a peripheral vein prior to cardioversion and ELISA was 
performed as described in chapter 2. Inter- and intra-assay coefficients of 
variation were <15%. Minimum limits of detection were; ICTP = 25 ng/mL, Gal-
3 = 0.156 ng/mL, FGF-23 = 15.625 pg/mL, PIIINP = 23.438 pg/mL. 
 
4.2.4 Echocardiography 
 
All participants underwent echocardiography as described in chapter 2. 
 
4.2.5 Statistical analysis 
 
Statistical analysis was performed in accordance with the description in chapter 
2. Univariate linear regression was used to assess the effect of baseline 
characteristics on biomarker levels. Variables with significant effects in 
univariate analysis were then examined in multivariate linear regression 
analysis. Univariate Cox regression analysis was used to assess predictors of 
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arrhythmia recurrence. A two-sided p value of 0.05 was used to determine 
statistical significance. 
 
4.2.6 Endpoints 
 
The endpoints for this study were: 
 
• A statistically significant association between biomarker levels and 
baseline clinical characteristics of AF patients undergoing DCCV. 
 
• A statistically significant difference between AF patients and controls 
 
• A statistically significant association between biomarker levels and 
recurrence of atrial fibrillation after DCCV, assessed by Cox regression. 
 
 
4.2.7 Power and sample size 
 
To calculate power, we hypothesized that there would be an increase of 0.5 
standard deviations in the levels of biomarkers in AF patients compared to 
controls. In order to achieve this variance using criteria of 1-β = 0.8 and p<0.05, 
35 patients per group would be required for the comparison part of the study. 
In order to achieve 80% statistical power to detect the difference in outcome 
based on biomarker levels, using p=0.05 to indicate significance, at least 20 AF 
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recurrence events would be required. Therefore, target recruitment was set at 
80 for the DCCV group and 40 for the control group. 
 
4.3 Results 
 
80 DCCV patients and 40 control patients were recruited. One patient was 
diagnosed with multiple myeloma after DCCV and died before follow up was 
complete. This patient’s data was excluded from analysis. Two further patients 
were lost to follow up. These patients were excluded from outcome analysis, 
but were included in baseline analysis.  
 
4.3.1 DCCV patients vs. controls 
 
Biomarker results were obtained as follows: for the AF group, ICTP n=76, Gal-
3 n=74, PIIINP n=38, FGF-23 n=27. For the control group, ICTP n=35, Gal-3= 
36, PIIINP n=31, FGF-23 n=12. Biomarker results were not available for all 
patients due to levels being above or below the detection ranges of the assay. 
The patient characteristics are summarised in table 1. LA volume and diameter 
were significantly higher in the DCCV group, but there were no other 
differences. Biomarker levels were not significantly different between the 
groups, although PIIINP levels were approaching significance for being higher 
in AF patients (p = 0.068). 
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4.3.2 Baseline characteristics and relationship to biomarkers 
 
For each of the four biomarkers, regression analysis was carried out to show 
relationships with patient characteristics across the DCCV cohort. Full results 
of this analysis are shown in table 2. In summary, statistically significant results 
after multivariate analysis were: Diabetes was related to higher PIIINP and 
FGF-23 levels; higher BMI, female sex, and hypertension were related to higher 
gal-3 levels. 
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Table 4-1 Baseline characteristics and comparison with controls 
Characteristic DCCV Group n=80 Control Group 
n=40 
P Value 
Age (years) 63.1 ± 9.9 62.2 ± 10.3 0.627 
BMI (kg/m2) 30.7 ± 7.2 29.0 ± 5.2 0.172 
Female sex 24 (30.0) 13 (32.5) 0.780 
Hypertension 42 (52.5) 21 (52.5) 1.000 
Diabetes Mellitus 9 (11.3) 6 (15) 0.558 
Ischaemic heart 
disease 
14 (17.5) 6 (15) 0.729 
Stroke or TIA 6 (7.5) 5 (12.5) 0.282 
Time since 1st AF 
diagnosis (months) 
6.6 (15.1) - - 
CHA2DS2VASc 
0 
1 
2 
3 
4 
5 
6 
 
14 (17.5) 
25 (31.3) 
17 (21.3) 
13 (16.3) 
7 (8.8) 
3 (3.8) 
1 (1.3) 
- - 
AAD 
 
10 (12.5) - - 
Rate – limiting drugs 
0 
1 
2 
3 
 
8 (10.0) 
58 (72.5) 
12 (15.0) 
2 (2.5) 
 
- 
 
- 
LA Volume (mL) 85.3 ± 25.8 56.4 ± 19.3 <0.001 
LA Diameter (mm) 44.4 ± 5.6 39.7 ± 5.9 <0.001 
LV EDV (mL) 105.3 ± 35.6 104.7 ± 32.5 0.941 
LV EF (%) 54.1 ± 11.9 59.0 ± 12.8 0.731 
Gal-3 (ng/mL) 25.2 (28.8) 25.9 (23.7) 0.194 
PIIINP (pg/mL) 53.5 (108.5) 42.7 (19.2) 0.068 
ICTP (ng/mL) 252.3 (190.4) 195.9 (315.2) 0.369 
FGF-23 (pg/mL) 31.5 (102.3) 91.8 (90.3) 0.916 
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Table 4-2 Regression analysis of biomarkers in relation to baseline 
characteristics, DCCV patients 
Characteristic PIIINP Gal-3 ICTP FGF-23 
Beta P 
Value 
Beta P Value Beta P 
Value 
Beta P 
Value 
Age 0.306 
0.444 
0.061 
0.088 
-0.025 0.832 -0.063 0.588 -0.050 0.806 
BMI -0.079 0.639 0.538 
0.424 
<0.001 
<0.001 
0.073 0.528 -0.114 0.572 
Female sex 1.396 0.171 0.312 
0.273 
0.007 
0.014 
-0.260 
-0.194 
0.023 
0.116 
-0.178 0.374 
Time since AF 
diagnosis 
0.351 
0.173 
0.033 
0.296 
-0.112 0.353 -0.081 0.494 -0.082 0.689 
Hypertension 0.117 0.483 0.387 
0.398 
0.001 
0.001 
-0.132 0.254 -0.479 
-0.355 
0.012 
0.055 
DM 0.273 
0.411 
0.098 
0.027 
0.174 0.139 -0.120 0.303 0.463 
0.455 
0.015 
0.007 
IHD 0.323 
0.058 
0.048 
0.770 
-0.010 0.932 -0.052 0.654 -0.148 0.461 
CVA or TIA -0.031 0.855 0.022 0.852 -0.186 0.107 -0.156 0.437 
CHA2DS2VASc 0.365 
-0.279 
0.024 
0.365 
0.263 
-0.410 
0.024 
0.736 
-0.244 
-0.166 
0.034 
0.176 
-0.388 
-0.219 
0.046 
0.226 
LA volume -0.244 0.146 -0.008 0.945 0.136 0.892 -0.044 0.837 
LA diameter -0.331 
-0.205 
0.042 
0.245 
0.013 0.915 0.127 
0.144 
0.283 0.053 0.801 
LV EDV -0.299 
-0.106 
0.097 
0.556 
-0.033 0.796 -0.002 0.985 -0.002 0.993 
LV EF -0.044 0.800 0.227 
0.138 
0.066 
0.169 
-0.006 0.961 -0.077 0.735 
Values in italics = multivariate analysis. Bold italics = statisitically significant after 
multivariate analysis. 
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4.3.3 Recurrence of AF after DCCV 
 
Duration of follow up was 383 ± 54 days. 49 patients (61.3%) experienced AF 
recurrence within the duration of follow up. Median AF-free survival was 170 
days. 
There were no significant differences between distribution of biomarker levels 
in patients with AF recurrence and those without. 
In univariate Cox regression analysis of all baseline characteristics (table 4-3), 
only FGF-23 was found to be weakly associated with arrhythmia recurrence 
(HR 1.003, p=0.012). 
 
Table 4-3 Univariate Cox regression analysis, AF recurrence 
Characteristic Hazard ratio P value 
Age 1.004 0.802 
BMI 1.013 0.506 
Female sex 0.624 0.124 
Time since first AF diagnosis 0.999 0.657 
Hypertension 0.831 0.519 
Diabetes mellitus 0.876 0.799 
IHD 0.681 0.351 
CVA or TIA 2.384 0.101 
CHA2DS2VASc 1.087 0.431 
LA volume 1.000 0.992 
LA diameter 1.000 0.994 
LV EDV 0.991 0.074 
LV EF 1.015 0.297 
PIIINP 1.002 0.292 
Gal-3 1.002 0.778 
ICTP 1.001 0.382 
FGF-23 1.003 0.012 
ICTP / PIIINP ratio 1.022 0.607 
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4.4 Discussion 
 
4.4.1 Selection of biomarkers 
 
The hallmark of fibrosis is an increase in volume and turnover of extracellular 
matrix (ECM). In the heart, ECM is comprised predominantly of type I, and to a 
lesser extent type III, collagen. PIIINP is cleaved from the pro-peptide of type 
III collagen in the extracellular space and thereby enters the bloodstream, so 
serves as a marker of the synthesis of type III collagen. It has been shown to 
be present in higher concentrations in LA tissue of AF patients [164]. ICTP is a 
product of the breakdown of type I collagen by matrix metalloproteinase 1 [164]. 
By including both of these substances in the study, the aim was to assess 
turnover of ECM, so the ratio of type I collagen catabolism to type III collagen 
synthesis was examined by ICTP:PIIINP ratio, however this value was not 
related to baseline characteristics or outcome. 
 
Gal-3, a member of the lectin family, has been found to have diverse direct and 
indirect actions associated with fibrosis in multiple tissues. It is associated with 
the presence of myofibroblasts and macrophages, which have been shown to 
proliferate in cardiac fibrosis. It appears to have activity related to cell adhesion, 
growth and differentiation, apoptosis and chemo-attraction, and has been 
associated with fibrogenesis, inflammation and ventricular remodelling [166-
168]. It has been associated with risk of developing AF, both in the general 
population, and after myocardial infarction [169, 170]. Studies assessing its 
association with arrhythmia recurrence after ablation have shown mixed results 
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[104, 118]. It has not been studied in the context of cardioversion previously. 
Higher levels have been associated with hypertension, female gender and 
higher BMI, and our findings agree [153, 171, 172].  
 
FGF-23 has come to light in recent years in the context of its endocrine role in 
phosphate homeostasis. It has been studied principally in heart failure and 
kidney disease, and does appear to be related to cardiac outcomes in the latter, 
as well as independently of renal function [173, 174]. In the fibrotic atrial 
myocardium found in AF, cardiomyocytes have been found to de-differentiate 
into a more primitive cell type [151]. FGF-23 has been shown in vitro to be 
required for cardiomyocyte proliferation and differentiation in early embryonic 
stages, and, speculatively, may have a role in the cardiomyocyte changes 
found in the fibrotic atria of AF patients, including calcium handling [174]. It has 
been associated with increased atrial wall tension manifest by NT-proBNP, but 
results of studies assessing its association with incident AF are mixed [129, 
150]. It has not been assessed in the context cardioversion previously. 
 
4.4.2 DCCV patients vs controls 
 
This study is, unique in comparing AF patients selected for DCCV to age and 
disease-matched controls when assessing biomarkers of fibrosis. There was 
no difference between levels of the four biomarkers between the DCCV patients 
and controls, which were well-matched for age and comorbidities. PIIINP levels 
approached significance for being higher in AF patients, suggesting that either 
there is no true difference, or perhaps that any true difference is so slight as to 
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be undetectable in a study of this size. Overall these findings are suggestive 
that either the DCCV patients had similar levels of fibrosis to the controls, or 
any differences in fibrosis were not detectable using these biomarkers 
peripherally. This may be accounted for by the fact that the controls were not 
disease-free, and comorbidity in the control group may have accounted for a 
rise in biomarker levels, therefore masking any specific contribution of AF to 
biomarker levels in the DCCV cohort. It may be the comorbidities present in AF 
patients that cause the increase in fibrosis biomarkers noted in other studies. It 
should be noted that one of the limitations of this study is the impossibility of 
excluding non-symptomatic paroxysmal AF in the control group, however it is 
unlikely that this would have been a significant problem. 
 
Previously, Sonmez et al. showed higher levels of gal-3 and PIIINP in AF 
patients compared to sinus rhythm age-matched controls, in a slightly smaller 
study [176]. While controls in that study were matched for most baseline 
characteristics, there was significantly higher heart failure in the AF group. This 
may have had an important confounding influence on their results, as both 
PIIINP and, more convincingly, gal-3 have been associated with reduced LV 
systolic function [104]. Gurses et. al. did find significantly higher levels of gal-3 
in AF patients, although in their study they excluded patients with reduced 
ejection fraction, which again makes comparison difficult [177]. Zakeri et al. 
found no gal-3 or PIIINP differences, and lower ICTP levels in controls [178]. 
However 23% of their sinus rhythm patients had a previous history of AF. They 
were also younger, with better LV function. In an AF ablation cohort, Kornej et 
al. also showed no difference between gal-3 in AF patients and controls after 
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multivariate analysis [103]. If nothing else, these studies highlight that work in 
this field involves heterogeneous patient groups between studies and it can 
therefore be difficult to draw firm conclusions regarding the overall AF patient 
population. In our study, only left atrial dimensions were different between the 
groups. As left atrial remodelling is a known effect of AF, this is to be expected. 
As the controls appear to be more well-matched than in other studies, the 
results are more robust.  
 
4.4.3 Predictive value of the biomarkers 
 
PIIINP, ICTP and Gal-3 had no predictive value for recurrence of AF. FGF-23, 
however, was found to be significantly, but weakly associated with recurrence, 
with a hazard ratio of 1.003 per 1 pg/mL increase in FGF-23 level. This result 
has not previously been reported, but must be interpreted with caution due to 
the low number of valid results for this biomarker compared to the overall 
number of patients, due to the limitations of the ELISA assay. It is possible that 
a more sensitive test may be able to explore this finding further. 
 
Gal-3 has not been studied in the context of DCCV, however in ablation results 
have been mixed. Kornej et al. found no association between AF recurrence 
and gal-3 levels in their ablation cohort [103]. Conversely Wu et. al. did show 
that gal-3 was associated with AF recurrence after ablation, however this 
finding is in the context of a younger cohort with lone AF so, again, is not 
comparable with this study [179]. 
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PIIINP was found to be independently associated with outcome by Kawamura 
et al. in their study of 142 patients undergoing pharmacological cardioversion, 
with DCCV if this failed [108]. Patients were followed up for 24 months. The 
baseline characteristics of patients in their study were similar to ours, with the 
notable exceptions of LV ejection fraction, which was lower in our cohort, and 
duration of AF which was much higher in our cohort. This may explain why this 
study did not reproduce their results, and we feel that our cohort more closely 
resembles ‘typical’ patients selected for DCCV, at least in our experience. 
 
Finally Kallergis et al. showed an association between recurrence and ICTP in 
their study of 164 DCCV patients. Notably however, they excluded patients with 
a significant number of comorbidities which may make their findings difficult to 
generalize to the AF population [179]. 
 
4.5 Conclusion 
 
PIIINP, ICTP, and Gal-3 are not predictive of AF recurrence after DCCV. FGF-
23 may be associated with arrhythmia recurrence, but further work is required 
to clarify this. The presence of AF has no effect on levels of these biomarkers 
when compared to age and disease-matched controls. 
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5 Left atrial voltage, circulating 
biomarkers of fibrosis, and 
atrial fibrillation ablation 
outcomes 
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5.1 Introduction 
 
Atrial fibrillation remains a significant cause of morbidity. For many patients, AF 
ablation has been shown to be a successful treatment, however approximately 
one third of patients undergoing the procedure will experience recurrence of 
AF, even after multiple procedures [180]. This figure may be as high as 50% 
for those with persistent AF [30]. Better patient selection may be one method 
of improving upon this. 
 
Left atrial (LA) fibrosis is associated with AF, and with AF recurrence after 
ablation [31]. Therefore, pre- and intra-procedural assessment of fibrosis may 
inform selection for first-time, or subsequent, ablation. 
 
Fibrosis involves numerous biochemical pathways, and component 
compounds of those pathways enter the bloodstream [162]. Such compounds, 
for example products and mediators of collagen turnover, can therefore be used 
as circulating biomarkers. There is conflicting evidence regarding their utility in 
predicting AF recurrence after ablation, however if such utility could be 
established they would be attractive to clinicians as a minimally invasive 
method of improved patient selection [162].  
 
After reviewing previous research in this field, four biomarkers were selected 
for study: Fibroblast growth factor 23 (FGF-23), galectin-3 (gal-3), type III 
procollagen N terminal peptide (PIIINP) and type I collagen C terminal 
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telopeptide (ICTP).  FGF-23 has not been studied in the context of recurrence 
after AF ablation previously.  
 
Low voltage areas identified during endocardial mapping of the LA can indicate 
increased likelihood of AF recurrence after ablation.[77] In previous studies 
assessing voltage as a predictor of rhythm outcome, the LA has been mapped 
while in sinus rhythm (SR) [77]. This is not necessarily representative of usual 
clinical practice, as patients in AF at the time of ablation are not routinely 
cardioverted before anatomical mapping. 
 
We hypothesized that the predictive effect of voltage mapping would be present 
in those patients who were mapped in both AF and in SR, and that increased 
levels of the selected biomarkers would predict AF recurrence after ablation. 
 
5.2 Methods 
 
5.2.1 Participants 
 
Written informed consent was obtained from all patients. At a single institution, 
between September 2014 and August 2015, all patients undergoing first-time 
left atrial ablation for paroxysmal, persistent, or long-standing-persistent AF 
were screened. Inclusion and exclusion criteria are described in chapter 3. 
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5.2.2 Echocardiography 
 
All participants underwent trans-thoracic echocardiography as described in 
chapter 2.  
 
5.2.3 Electrophysiological mapping and ablation 
 
Left atrial mapping was carried out as described in chapter 2. Figure 5-1 shows 
the resulting left atrial voltage maps. Ablation was carried out as described in 
chapter 2. 
 
5.2.4 Serum ELISA analysis 
 
Blood sampling and ELISA was carried out as described in chapter 2. Inter- and 
intra-assay coefficients of variation were <15%. %. Lower limits of detection 
were: ICTP = 25ng/mL, gal-3 = 0.156ng/mL, FGF-23 = 15.625pg/mL, PIIINP = 
23.438 pg/mL.  
 
 
Overleaf: Figure 5-1 Representative LA voltage maps of 4 separate patients 
prior to sectioning of veins, appendage and mitral valve. Top row; patients 
mapped in AF. Bottom row; patients mapped in SR. Left column < 30% area 
low voltage. Right column, > 30% area low voltage Red areas represent 
<0.5mV. LLPV = left lower pulmonary vein, LUPV = left upper pulmonary vein, 
RLPV = right lower pulmonary vein, RUPV = right upper pulmonary vein, LAA 
= left atrial appendage. 
 LLPV 
LLPV 
LLPV 
LLPV 
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LUPV 
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5.2.5 Endpoints 
 
Planned follow-up duration was 365 days. Arrhythmia recurrence was defined 
as symptomatic or asymptomatic atrial fibrillation, or atrial tachycardia, with a 
duration of longer than 30 seconds, diagnosed on 12 – lead ECG or Holter 
monitor. In patients who experienced no recurrence according this criterion at 
follow-up, 24 hour Holter monitoring was performed to screen for asymptomatic 
arrhythmia. 
 
The primary endpoint was arrhythmia recurrence after a 60-day blanking 
period. However, to adjust for recurrences due to pulmonary vein re-connection 
(as opposed to atrial fibrosis or other cause) a secondary endpoint was defined. 
This endpoint took into account the effect of multiple procedures, and was 
defined as either a recurrence of arrhythmia after one procedure with no further 
intervention planned, or a recurrence of arrhythmia after a repeat procedure. 
Therefore, patients with recurrence after a single procedure, but no recurrence 
after a repeat ablation were not included in the secondary endpoint. 
 
5.2.6 Statistical analysis 
 
Statistical analysis was performed as described in chapter 2. To examine time-
to-outcome data, univariate Cox regression analysis was performed, followed 
by multivariate analysis using selected variables of interest (see results). 
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Analysis was carried out using SPSS version 22. For power and sample size 
see chapter 3.2.6
  
Figure 5-2 Study outline
 5.3 Results 
 
Figure 5-2 shows participant recruitment and progression through the study. As 
described in chapter 3, 98 ablation patients were screened. 3 patients failed 
screening due to meeting exclusion criteria. No patients refused to consent. 95 
patients were therefore recruited into the ablation cohort. Two of these patients 
subsequently elected not to undergo ablation and were excluded. One 
procedure was abandoned due to pericardial bleeding after EP mapping and 
blood sampling, but before ablation. No further ablation was attempted, so this 
patient could not be included in outcome analysis. 60 patients were in sinus 
rhythm during atrial mapping, 32 were in AF. 4 patients received cavo-tricuspid 
isthmus ablation due to documented typical atrial flutter as well as AF. No 
patients underwent CFAE ablation. Linear ablation was performed in only 2 
patients due to sustained left atrial flutter being occuring during the procedure. 
All patients had drug-refractory AF, defined by ongoing symptoms after therapy 
with at least 2 consecutive or concurrent agents, or unacceptable side-effects 
thereof. 
 
5.3.1 Biomarker levels, LA voltage and baseline characteristics. 
 
Full presentation and analysis of baseline characteristics is described in 
chapter 3. Tables 5-1 and 5-3 show the baseline characteristics of the cohort, 
separated by the endpoints. Mean LA voltage was higher in those mapped in 
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SR than in AF (1.3 V  0.6 V vs 0.8 V  0.4 V, p = 0.037). The findings of cross 
sectional analysis of the biomarkers levels within the cohort, at different 
sampling sites, and comparison with controls, is described in chapter 3. In 
summary, after multivariate regression analysis, higher BMI was related to 
higher gal-3 (P<0.001), as was female sex (p=<0.001). Reduced LV ejection 
fraction (LVEF) was related to higher ICTP (p=0.005). PIIINP levels were 
related to longer time since AF diagnosis (p=0.003) and the presence of a 
history of cerebrovascular disease (p=<0.001). There was no significant 
association between any of the biomarkers and proportion of low voltage in the 
LA. There was no significant difference between levels of FGF-23 or PIIINP 
across sampling sites, so levels are quoted as a mean value of all four sampling 
sites. ICTP at the CS and gal-3 at the LA were shown to be significantly different 
from peripheral levels, so levels at these sites are shown in addition to the 
mean. 
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5.3.2 Primary endpoint 
 
Table 5-1 Baseline characteristics according to primary endpoint (first 
procedure recurrence) 
Characteristic AF recurrence n=42 No AF recurrence n=50 P value 
Age years 56.0 (22.9) 60.1 (17.48) 0.956 
BMI kg/m2 25.3 (5.0) 28.9 (6.89) 0.327 
Female sex 11 (26.2%) 17 (34.0%) 0.417 
Hypertension 13 (31.0%) 18 (36.0%) 0.610 
Diabetes Mellitus 6 (14.3%) 3 (6.0%) 0.183 
IHD 2 (4.8%) 3 (6.0%) 0.794 
Non-PAF 15 (35.7%) 15 (30.0%) 0.560 
Time since 1st AF diagnosis 
months 
34.3 (33.4) 24.3 (53.85) 0.420 
CHA2DS2VASc >= 2 15 (35.7%) 20 (40.0%) 0.673 
Mean LA Pressure >11mmHg 24 (57.1%) 32 (64.0%) 0.811 
Mean RA Pressure >6mmHg 23 (54.8%) 20 (40.0%) 0.068 
LA volume / BSA >28 mL 24 (57.1%) 27 (54.0%) 0.886 
LA diameter / BSA >23 mm 5 (11.9%) 4 (8.0%) 0.538 
LV EDV / BSA >75 mL 0 (0.0%) 2 (4.0%) 0.204 
LV EF <55% 5 (11.9%) 3 (6.0%) 0.285 
Mean PIIINP pg/mL (n=69) 51.6 (91.1) 44.9 (115.1) 0.156 
Mean ICTP ng/mL (n=79) 329.4 (190.1) 300.0 (373.0) 0.121 
CS ICTP ng/mL (n=76) 297.5 (209.2) 331.7 (253.6) 0.314 
Mean gal-3 ng/mL (n=81) 30.8 (75.4) 24.5 (40.0) 0.510 
LA gal-3 ng/mL (n=81) 18.17 (37.1) 24.8 (31.6) 0.709 
Mean FGF-23 pg/mL (n=33) 32.6 (45.5) 50.5 (62.8) 0.313 
LA low voltage >30.0%, all 
participants (n=92) 
15 (35.7%) 8 (16.0%) 0.030 
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During the 365-day follow-up, 42 patients met the primary endpoint. 28 of these 
patients had been mapped in SR, 14 in AF. Comparison between the 
characteristics of those who met the primary endpoint and those who did not is 
shown in table 5-1. For variables with clearly defined normal ranges (e.g. 
echocardiographic measurements), continuous data was categorized 
accordingly. For the biomarker levels, receiver-operator curves (ROC) were 
generated which revealed no predictive value (area under the curve (AUC) for 
mean ICTP = 0.375, ICTP CS = 0.410; mean gal-3 = 0.478, gal-3 LA = 0.483; 
mean PIIINP 0.586; mean FGF-23 = 0.481). Further outcome analysis was 
therefore not carried out on the biomarkers. ROC for LA voltage (AUC = 0.653) 
suggested that values in the 4th quartile (>30.0% low voltage) were stronger 
predictors of the endpoint, so data was categorised according to this. For those 
patients with >30% low voltage, the primary endpoint was met in 16 of 23 
patients (69.6%), for those with less than 30% scar, 26 of 69 patients met the 
primary endpoint (37.6%), p=0.04. LA low voltage was analysed for those 
mapped in SR, AF and for the cohort as a whole. Those patients who met the 
primary endpoint had significantly higher proportion of LA low voltage tissue in 
the whole cohort (p = 0.030), and in those mapped in SR (p = 0.042), but not 
those mapped in AF (p = 0.178). This variable was therefore entered into a 
multivariable analysis with other variables of interest, including predictors of AF 
recurrence published in other studies. These variables were age, body mass 
index (BMI), sex, LA volume, AF classification, AF duration (table 5-2). 
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Table 5-2 Cox regression, LA low voltage proportion, primary endpoint 
 Hazard ratio (95% CI) P value 
LA low voltage >30.0%, all 
participants 
3.448 (1.626 – 7.313) 
3.494 (1.600 – 7.633) 
0.001 
0.002 
LA low voltage >30.0%, SR during 
mapping 
4.471 (1.384 – 14.441) 
4.323 (1.337 – 13.982) 
0.012 
0.014 
LA low voltage >30.0%, AF during 
mapping 
4.477 (1.167 – 17.170) 
5.195 (1.032 – 26.141) 
0.029 
0.046 
Italics = multivariate analysis. Variables entered into multivariate regression analysis: Age, body 
mass index, sex, LA volume / BSA, AF classification, AF duration – all were non-significant 
 
 
Proportion of LA low voltage remained the only significant predictor variable in 
this analysis whether the patient was mapped in AF (hazard ratio 5.195, 95% 
confidence interval 1.032 – 26.141, p=0.046) or SR (HR 4.323, 95%CI 1.337 – 
13.982, p = 0.014). 
 
Figure 5-3 shows cumulative freedom from AF, according to the primary 
endpoint, in the overall cohort, AF and SR-mapped patients. Curves are 
separated by 4th versus combined other quartiles of LA low voltage proportion. 
Figure 5-3 Freedom from AF assessed by primary endpoint, separated by LA low voltage proportion >30.0%, mapped in SR and AF. 
 
 5.3.3 Secondary Endpoint 
 
Table 5-3 Baseline characteristics according to secondary endpoint 
Characteristic Met secondary endpoint 
n=32 
Did not meet secondary 
endpoint n=60 
P value 
Age years 58.6 (20.1) 57.8 (16.9) 0.296 
BMI kg/m2 26.9 (9.6) 28.9 (7.4) 0.861 
Female sex 9 (28.1%) 19 (31.7%) 0.725 
Hypertension 9 (28.1%) 22 (36.7) 0.409 
Diabetes Mellitus 5 (15.6%) 4 (6.7%) 0.168 
IHD 2 (6.3%) 3 (5.0%) 0.801 
Non-PAF 12 (37.5%) 18 (30.0%) 0.465 
Time since 1st AF diagnosis 
months 
34.4 (29.6) 32.7 (34.8) 0.641 
CHA2DS2VASc >= 2 11 (34.4%) 24 (40.0%) 0.597 
Mean LA Pressure >11mmHg 17 (53.1%) 39 (65.0%) 0.384 
Mean RA Pressure >6mmHg 18 (56.3%) 25 (41.7%) 0.152 
LA volume / BSA >28mL 20 (62.5%) 31 (51.7%) 0.261 
LA diameter / BSA >23 mm 5 (15.6) 4 (6.6%) 0.151 
LV EDV / BSA >75 mL 0 (0.0%) 2 (3.3%) 0.325 
LV EF <55% 4 (12.5%) 4 (6.7%) 0.276 
Mean PIIINP pg/mL (n=69) 51.9 (100.2) 39.6 (78.74) 0.492 
Mean ICTP ng/mL (n=79) 290.8 (267.2) 333.7 (344.9) 0.114 
CS ICTP ng/mL (n=76) 305.7 (163.2) 328.4 (275.8) 0.829 
Mean gal-3 ng/mL (n=81) 36.1 (75.4) 24.1 (35.3) 0.938 
LA gal-3 ng/mL (n=81) 17.7 (47.5) 26.1 (31.6) 0.888 
Mean FGF-23 pg/mL (n=33) 34.5 (29.6) 46.8 (60.7) 0.808 
LA low voltage >30.0%, all 
participants (n=92) 
11 (34.4%) 12 (20.0%) 0.129 
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As seen in figure 5-2, there were 18 and 14 secondary endpoints in the SR and 
AF groups, respectively. Table 5-3 shows comparison of baseline 
characteristics. Again, none of the biomarkers levels or clinical characteristics 
(including LA low voltage) were significantly different. LA low-voltage was again 
analysed with Cox regression (table 5-4). The same variables were used for 
multivariate regression. LA low voltage remained a significant predictor whether 
the LA was mapped in SR (HR 10.375, 95%CI 2.049 – 52.538, p = 0.005) or 
AF (HR 6.200, 95%CI 1.194 – 32.194, p = 0.030). Due to the reduction in 
number of endpoints, confidence intervals were wider for this endpoint 
definition. 
 
Table 5-4 Cox regression, LA low voltage proportion, secondary endpoint 
 Hazard ratio (95% CI) P 
LA low voltage >30.0%, all 
participants 
4.084 (1.944 – 8.580) 
5.000 (2.042 – 12.244) 
<0.001 
<0.001 
LA low voltage >30.0%, SR 
during mapping 
4.832 (1.503 – 15.532) 
10.375 (2.049 – 52.538) 
0.008 
0.005 
LA low voltage >30.0% AF 
during mapping 
3.565 (1.050 – 12.106) 
6.200 (1.194 – 32.194) 
0.042 
0.030 
Italics = multivariate analysis. Variables entered into multivariate regression 
analysis: Age, body mass index, sex, LA volume / BSA, AF classification, AF 
duration – all were non - significant 
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Comparison of low voltage LA proportion in those patients with arrhythmia 
recurrence but no repeat procedure, and those who had a repeat procedure, 
revealed no difference (27.8% ± 12.9% vs. 27.6% ± 9.2%, p=0.967). This 
comparison was carried out to look for evidence of selection bias when planning 
repeat procedures. 
Figure 5-3, overleaf, shows cumulative freedom from AF, according to the 
primary endpoint, in the overall cohort, AF and SR-mapped patients. Curves 
are separated by 4th versus combined other quartiles of LA low voltage 
proportion.
  
 
Figure 5-4 Freedom from AF assessed by secondary endpoint, separated by LA low voltage proportion >30.0%, mapped in SR and 
AF. 
5.4 Discussion 
 
5.4.1 Findings 
 
None of the biomarkers assessed in this study were predictive of arrhythmia 
recurrence after AF ablation, as assessed by either of the endpoints. Proportion 
of low voltage in the LA was predictive of arrhythmia recurrence after a single 
procedure, whether the LA was mapped in SR or AF. This effect remained when 
repeat procedures were taken into account. 
 
5.4.2 Biomarkers 
 
The background of these biomarkers, and the reasons for choosing to study 
them, have been previously discussed [182]. 
 
This study found that none of the biomarkers selected was predictive of AF 
recurrence. This therefore adds to the conflicting evidence regarding PIIINP, 
ICTP and Gal-3 [103, 104, 114, 118]. FGF-23 has not been studied in this 
context before. The challenge when using biomarkers to assess a pathology is 
specificity. In this instance, the goal is to assess cardiac fibrosis, specifically, 
LA fibrosis. As discussed, while these biomarkers have been shown to be 
involved in cardiac pathology both in vitro and in vivo, they are far from 
exclusively so. Therefore, the blood levels are liable to be affected by fibrosis 
elsewhere in the body. For example, we have previously shown that ICTP and 
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gal-3 have lower intra-cardiac than peripheral levels, with no significant 
difference in the cases of FGF-23 and PIIINP [182]. Therefore, it appears that 
if any AF-related cardiac processes are indeed causing release of these 
biomarkers into the bloodstream, systemic fibrosis masks this in peripheral 
blood 
 
A further challenge is the large degree of scatter exhibited in the levels of the 
biomarkers. This may be in part due to limitations of the ELISA technique, but 
may also again reflect the diversity of processes in which these biomarkers are 
involved. Such degrees of variation make prediction on an individual patient 
basis challenging. 
 
The findings of this study refute the hypothesis and suggest that, for these 
biomarkers at least, there is no clinical utility in the prediction of arrhythmia 
recurrence, and therefore they are no aid to patient selection. 
 
5.4.3 Voltage 
 
The findings of this study are in agreement with the larger 2005 study by Verma 
et al. which found that low voltage areas in the LA were the only predictor of AF 
recurrence after multivariate analysis [77]. The method of assessing the 
presence of low voltage differs between the two studies. Rather than defining 
discrete areas of scarring within the atrium and treating this as a binary variable, 
this study shows that the approach of quantifying low voltage values as a 
proportion of the LA endocardium as a whole is sufficient to have a predictive 
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effect for rhythm outcome. The study has also shown that this effect is present 
using a high-density mapping catheter without the need for intra-cardiac 
ultrasound. The use of a contact force-sensing ablation catheter during the 
ablation was sufficient to validate the shell. The upper voltage threshold of 
0.5mV has been suggested by a number of studies as a cutoff between normal 
and abnormal tissue [77, 183]. It should be noted that these studies mapped 
patients in sinus rhythm. The lack of voltage reference criteria in AF-mapped 
patients could be considered a limitation of this study. However, despite clear 
differences in overall LA voltage values in AF-mapped patients compared to 
SR-mapped patients, the same threshold of 0.5mV showed utility in predicting 
AF recurrence in both groups. While EP mapping is not a useful tool in the 
selection of patients for first-time ablation procedures, such voltage information 
may be useful to the operator when considering repeat procedures. Therefore, 
as approximately one third of patients who undergo ablation are in AF at the 
start of the case, it is useful to know that voltage analysis remains relevant. 
These findings support the hypothesis. 
 
Most studies have used recurrence after first-time ablation as an endpoint. 
However, this does not allow for the effect of PV re-connection due to tissue 
healing, or resolution of transient causes of electrical block such as oedema. 
Recurrences due to these phenomena are not a result of fibrosis. Therefore, 
we also used a secondary endpoint that took multiple procedures into account. 
The significant predictive effect of LA voltage was present for both endpoints, 
although confidence intervals for the hazard ratio were wide due to the lower 
number of patients meeting the secondary endpoint. Although the analysis of 
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voltage was carried out after the ablation procedure, operators could not be 
blinded to the standard CARTO 3 or Ensite Velocity visual voltage map 
during cases, so in order to assess whether later selection for repeat ablation 
had been influenced by voltage maps from the index procedure, we compared 
voltage values of recurrent AF patients who underwent redo procedures with 
those who did not, and found no difference. This suggests that selection bias 
did not play a significant role. 
 
 
5.4.4 Strengths and limitations 
 
The study population represents a ‘real-world’ AF ablation population with 
minimal exclusion criteria, and the findings should therefore be generalizable. 
Caution should be employed when interpreting the findings involving FGF-23 
as results were not available for a large proportion of the patients, however we 
have included this in the results as this biomarker has not been studied in this 
context previously. In order to confirm the predictive value of voltage mapping 
in AF using the secondary endpoint, a larger trial is required. Finally, although 
Holter monitoring was used to detect asymptomatic recurrences, undetected 
asymptomatic recurrences cannot be completely ruled out. The lack of 
relationship between voltage and any baseline characteristics may be related 
to the smaller numbers in this study compared to others. 
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5.5 Conclusions 
 
ICTP, PIIINP, Gal-3 and FGF-23 are not predictive of AF recurrence after RF 
ablation. 
 
The presence of low voltage tissue within the atrium, assessed using a semi-
automated technique, is predictive of AF recurrence when the atrium is mapped 
in SR or AF. Further development of this may allow operators to improve 
assessment of the likelihood of AF recurrence in their patients. 
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6 Combined imaging, biomarker 
and invasive assessment of 
diffuse cardiac fibrosis in atrial 
fibrillation 
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6.1 Introduction 
Percutaneous ablation is often used for rhythm control in patients with atrial 
fibrillation (AF). However, at least one third of such patients experience a 
recurrence of AF even after multiple procedures [184]. This is most commonly 
due to reconnection of the pulmonary veins, however in a significant proportion 
of patients this is not the case and the mechanism(s) in these instances is 
unclear. Identification of AF patients who are likely to maintain sinus rhythm 
after the procedure is important, to reduce unnecessary exposure to procedural 
risks. 
 
Fibrosis is a hallmark of the LA pathological changes associated with AF 
development and recurrence after ablation [163, 185]. It can be identified by 
pre-ablation LGE-CMR, which has been shown to predict arrhythmia 
recurrence and therefore potentially has a role in patient selection [98]. Also, 
low voltage areas in the LA, identified by EP mapping, are thought to relate to 
atrial fibrosis and are associated with arrhythmia recurrence, as demonstrated 
earlier in this thesis and in other studies [77]. 
 
LV fibrosis is more prominent in AF patients than those without AF, and may 
be a predictor of AF recurrence [138, 186]. Diffuse LV fibrosis can be estimated 
using CMR, by calculating the extracellular volume fraction (ECV) from native 
and post-contrast T1 mapping [133]. 
 
Circulating biomarkers such as type I collagen C terminal telopeptide (ICTP), 
type III procollagen N terminal peptide (PIIINP) and galectin 3 (gal-3) are 
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markers of fibrosis that can be measured in the bloodstream [162]. They offer 
minimally invasive assessment of fibrosis, and would be a useful tool for 
improving patient selection if their clinical utility in doing so could be confirmed. 
They may also have a research application, in defining the mechanism of AF. 
 
Although LA and LV fibrosis have both been associated to some extent with AF 
and AF recurrence, the mechanism behind this predictive effect and the link 
between LA and LV fibrosis are less clear. Raised LA pressure has been 
associated with recurrence of AF after catheter ablation, however the 
relationship between LA pressure and cardiac fibrosis in AF patients has not 
been studied in depth [187]. LA pressure is a routinely available measurement 
during AF procedures after trans-septal puncture, and further study may 
provide mechanistic insights into any haemodynamic influence on LA and LV 
fibrosis in this patient group.  
 
The interaction between LA fibrosis, LV fibrosis and LA pressure, all of which 
are associated with arrhythmia recurrence in patients after AF ablation, was 
investigated in this study. This interaction was examined in a multi-modality 
fashion, using CMR, EP mapping, LA pressure measurement and circulating 
biomarker assays. It was hypothesized that LA fibrosis on LGE-CMR is 
associated with diffuse LV fibrosis measured by ECV mapping and that raised 
LA pressure is associated with both LA and LV fibrosis.  To attempt to gain a 
mechanistic insight into the pathological process of the fibrosis identified via 
these imaging methods, levels of circulating fibrosis biomarkers were analysed 
as previously described, including from intracardiac blood. 
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6.1 Methods 
 
Thirty-one patients undergoing first-time LA ablation for paroxysmal, persistent, 
or long-standing-persistent AF were recruited at a single centre between 
September 2014 and August 2015. Patients were part of the larger ablation 
cohort undergoing biomarker testing, and sample size was dictated by the 
number of patients who consented to, and could be scheduled for, CMR prior 
to ablation. Inclusion criteria were as described in chapter 3. Patients with 
systemic inflammatory disease, recent or active malignancy, severe kidney 
disease (eGFR<30mL/min/1.73m2) connective tissue disease, or any contra-
indication to CMR were excluded. 
 
6.1.1 CMR 
 
CMR scans were carried out according to the methods described in chapter 2. 
Figure 6-1 provides and overview of the steps taken in LA LGE analysis in a 
representative selection of cases. 
 
6.1.2 Radiofrequency ablation 
 
Radiofrequency (RF) ablation was performed according to the methods 
described in chapter 2, including blood sampling, electrophysiological mapping, 
and LA pressure measurement. 
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6.1.3 ELISA 
 
Biomarker ELISA was carried out as described in chapter 2. Due to limitations 
of the ELISA, too few valid results for FGF-23 were attained, therefore this 
biomarker was not analysed in this study. 
 
ICTP levels were analysed from coronary sinus blood, gal-3 and PIIINP levels 
were analysed as a mean of peripheral and intra-cardiac levels, based on the 
findings described in chapter 3. 
 
6.1.4 Endpoints 
The following endpoints were tested for: 
 
• Association between LA-LGE and biomarker levels 
 
• Association between LA-LGE and LA scar proportion identified by low 
voltage on electro-anatomical mapping. 
 
• Association between biomarkers and LV ECV. 
 
• Associations between LA pressure and biomarkers, LA-LGE, electro-
anatomical mapping data, and LV ECV. 
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6.1.5 Follow up 
 
All patients were followed up for 365 days. In patients without documented 
arrhythmia recurrence at this point, 24-hour ECG was performed. Arrhythmia 
recurrence was defined as any documented AF or atrial arrhythmia lasting more 
than 30 seconds, occurring more than 60 days after ablation. 
 
6.1.6 Statistical analysis 
 
Basic statistical methodology is described in chapter 2. Patients were 
compared with above (i.e., more fibrosis) and below (i.e., less fibrosis) median 
CMR values of LA LGE and LV ECV. Differences in characteristics between 
these groups were then assessed using independent-sample t-tests for 
continuous variables or chi-squared tests for categorical variables. Where 
transformation of non-parametric data was not possible, Mann-Whitney U test 
was performed to compare distributions. Univariate linear regression analysis 
was performed to examine relationships between % LA LGE, LV ECV, and 
baseline characteristics. For the multivariable analysis, a forward selection 
process was used to identify predictors. Analysis was carried out using SPSS 
version 22 (IBM Corp., Armonk, NY). A 2-sided P-value of <0.05 was 
considered to indicate statistical significance. 
 
6.2 Results 
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6.2.1 Participants 
 
All 31 recruited had CMR assessment of LV. LA CMR assessment could not be 
completed on one participant, due to movement artefact. The participants were 
typical of AF ablation patients and had few comorbidities apart from 
hypertension (table 6-1). Mean LA volume of the cohort was elevated above 
the normal reference range. All patients had LV ejection fraction (LVEF) more 
than 45%. The majority (80.6%) had paroxysmal AF (PAF), and the remainder 
had either persistent or long-standing persistent AF, grouped together for 
analysis as ‘non-PAF’. No patient had obstructive sleep apnoea. All patients 
had an ECG QRS duration of less than 120ms. 
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Table 6-1 participant characteristics 
 
Characteristic Distribution 
Age (years) 56.7 ± 12.7 
BMI (kg/m2) 27.5 (5.9) 
Sex 
Female 
Male 
 
9 (29.0) 
22 (71.0) 
AF classification 
Paroxysmal 
Non-paroxysmal 
 
25 (80.6) 
6 (19.4) 
Time since AF diagnosis (months) 51.3 (53.9) 
In AF during CMR scan 9 (29.0) 
Diabetes mellitus 1 (3.2) 
Ischaemic heart disease 2 (6.5) 
Hypertension 9 (29.0) 
Systolic BP (mmHg) 125.2 ± 23.4 
Diastolic BP (mmHg) 77.6 ± 14.5 
LA Volume (mL) 102.1 ± 40.2 
LV EDV (mL) 157.6 ± 37.4 
LV SV (mL) 92.9 ± 23.7 
Cardiac output (L/min) 6.3 ± 1.6 
LV EF (%) 59.2 ± 7.1 
LV Mass (g) 87.3 ± 24.7 
LV ECV (%) 24.1 ± 2.5 
Mean LA pressure 
(mmHg) 
9.0 (5.0) 
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6.2.2 CMR assessment of LA and LV fibrosis 
 
Figure 6-1. 5 representative cases. First column = LGE image. Second column 
= Same LGE image slice with LA segmentation superimposed. Third column = 
MRI-derived scar map before removal of PVs and mitral valve. Fourth column 
= endocardial voltage derived from contact mapping. Fifth column = 3D 
representation of the MRI LGE image and segmentation 
 
 
 
Patients with above median (‘high’) LA LGE values (i.e., >17.8%) were 
compared to those with below median (‘low’) LA LGE values. LV ECV was 
higher in the high LA LGE group (24.9±2.2% vs. 23.0±2.1%, p=0.026) 
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suggesting more LV fibrosis in patients with more LA fibrosis (Table 6-2, figure 
6-2). BMI and LV mass index were lower in the high LA LGE group. No other 
differences were identified. Table 3 shows the results of regression analysis. 
Univariate analysis revealed several associations approaching significance, but 
after multivariable regression, the only significant association with LA LGE were 
time since AF diagnosis ( = 0.473, p = 0.006) (see table 3 and later comment 
regarding gal-3). No association between LA LGE and LV ECV was found in 
the regression analysis. 
 
 
Figure 6-2 overleaf. Associations between biomarkers, LA LGE and LV ECV
 
Table 6-2 Left atrial and left ventricular fibrosis comparisons 
 LA LGE LV ECV 
Above median 
LA LGE 
Below median 
LA LGE 
P value Above median 
LV ECV 
Below median 
LV ECV 
P Value 
LV ECV (%) 24.9±2.2 23.0±2.1 0.026 - - - 
ICTP ng/mL 332.9 (242.7) 240.2 (241.2) 0.120 450.7 (154.4) 212.1 (146.3) 0.001 
Galectin-3 ng/mL 13.0 (32.0) 29.8 (29.8) 0.041 29.2 (19.4) 43.5 (41.8) 0.241 
PIIINP pg/mL 72.7 (112.1) 64.7 (45.3) 0.688 63.4 (50.4) 87.2 (58.0) 0.413 
LA voltage (% < 0.5mV) 20.7±8.3 20.6±6.1 0.973 22.3±7.0 17.4±6.6 0.102 
Mean LA pressure (mmHg) 8.0 (5.3) 9.0 (5.0) 0.422 12.9±5.5 8.1±3.5 0.010 
 
Age (years) 59.5±13.1 55.4±11.2 0.376 56.5±13.0 56.9±12.9 0.918 
Time since AF diagnosis 
(months) 
56.3 (89.9) 48.8 (74.6) 0.583 29.6 (39.9) 63.0 (67.9) 0.010 
BMI (kg/m2) 25.8 (3.3) 29.7 (6.6) 0.005 27.4±4.3 29.3±6.0 0.316 
LA vol/BSA (mL/m2) 49.0 (30.9) 47.33 (15.7) 0.683 46.6 (21.5) 42.9 (15.9) 0.740 
LV EDV/BSA (mL/m2) 69.8±12.9 80.2±16.0 0.063 71.4±14.4 79.3±14.9 0.150 
LV EF (%) 59.9±7.8 59.5±5.7 0.883 61.0±7.5 57.2±6.2 0.140 
LV Mass/BSA (g/m2) 37.1 (11.8) 43.0 (9.8) 0.033 43.3 (8.7) 39.1 (10.1) 0.522 
Systolic BP (mmHg) 124.6±27.0 126.9±14.2 0.798 122.8±21.3 127.4±25.8 0.590 
Diastolic BP (mmHg) 74.3±14.0 79.5±14.1 0.315 78.9±12.1 76.3±17.0 0.616 
PAF 11 (73.3) 14 (93.3) 0.142 13 (86.7) 12 (80.0) 0.930 
Male 11 (73.3) 11 (73.3) 1.00 10 (66.7) 12 (80.0) 0.283 
SR during scan 9 (60.0) 13 (86.7) 0.099 11 (73.3) 11 (73.3) 1.00 
Recurrence of AF 8 (53.3) 7 (46.7) 0.715 8 (53.3) 7 (46.7) 0.715 
The median value for LA LGE is 17.8%. The median value for LV ECV is 24.0%. Values are ‘mean ± standard deviation’, ‘median (interquartile range)’ or ‘frequency (%)’. P values represent 
results of Student’s t-test for normally distributed data, Mann-Whitney U test for non-parametric data, and chi-squared test for categorical data. Statistically significant results highlighted in bold. 
BMI = body mass index, BSA = body surface area, BP = blood pressure. 
Table 6-3 Regression analysis 
Characteristic Association with ECV Association with LA LGE 
Beta P Value Beta P Value 
Age (years) -0.172 0.354 0.037 0.844 
Time since AF diagnosis 
(months) 
0.038 0.849 0.555 
0.507 
0.003 
0.004 
BMI (kg/m2) -0.267 0.146 -0.317 0.108 
Female sex 0.296 0.106 -0.148 0.460 
Non - PAF 0.116 0.535 0.343 0.080 
Hypertension 0.103 0.582 0.258 0.169 
CHA2DS2VASc 0.008 0.964 0.232 0.244 
LA vol (mL) -0.247 0.181 -0.053 0.791 
LV EDV (mL) -0.294 0.115 -0.297 0.140 
LV EF (%) 0.184 0.330 -0.039 0.851 
LV Mass (g) -0.250 0.183 -0.321 0.109 
Systolic BP (mmHg) 0.033 0.859 0.192 0.849 
Diastolic BP (mmHg) 0.069 0.714 -0.060 0.767 
Mean LA pressure (mmHg) 0.486 
0.791 
0.008 
<0.001 
0.076 0.381 
LA LGE (%) 0.258 0.169 - - 
LV ECV (%) - - 0.250 0.208 
LA voltage (<0.5mV) 0.257 0.225 -0.189 0.425 
ICTP 0.754 
0.592 
<0.001 
0.001 
0.245 0.238 
PIIINP -0.004 0.989 -0.272 
-. 
0.291 
Gal-3 -0.142 0.454 -0.385 
-0.337 
0.039 
0.047 
Results in italics represent multivariable analysis results. Results in bold represent statistically 
significant associations after multivariable analysis  
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Table 6-2 shows the results of the comparisons between the cohort when split 
above and below the median LV ECV value of 23.9%. The above-median LV 
ECV group had higher mean LAP (12.9±5.5 mmHg vs. 8.1±3.5 mmHg, p = 
0.010). This association was seen to be significant after multivariable analysis 
(=0.791, p<0.001) (table 6-3). No other differences were identified. It should 
be noted that despite 2 patients having a clinical diagnosis of ischaemic heart 
disease, only one of these patients had demonstrable LV late gadolinium 
enhancement. Exclusion of this patient’s data from the T1 analysis made no 
significant difference to the results, and it was included. 
 
Percentage LA low voltage was not found to be significantly different with 
respect to either LA LGE or LV ECV levels. 
 
6.2.3 Biomarkers 
 
Galectin-3 levels were lower in the above-median LA LGE group (13.0 (32.0) 
ng/mL vs 29.8 (29.8) ng/mL p=0.041), however this relationship was found to 
be of borderline significance on multivariable analysis ( -0.337 p=0.047, table 
6-3), a likely result of the differences in BMI across the LA LGE group. Statistical 
correction for this effect was not appropriate in a cohort of this size (see 
discussion). The above-median LV ECV group had higher ICTP levels (450.7 
(154.4) ng/mL vs. 212.1 (146.3) ng/mL, p=0.001) (Figure 2) and the difference 
remained significant after multivariable analysis (=0.592, p=0.001) (table 3). 
There were no differences in levels of galectin-3 or PIIINP with respect to LV 
ECV, or between levels of PIIINP or ICTP with respect to LA LGE. 
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6.3 Discussion 
 
6.3.1 Associations with LV ECV 
 
We have shown in this study that mean LAP is associated with LV ECV in AF 
patients. The association between AF and ventricular fibrosis is less well 
established than atrial fibrosis, but LV fibrosis appears to be more pronounced 
in AF patients than in non-AF controls [188]. A potential mechanistic 
explanation for this exists; LV end-diastolic pressure is elevated in the presence 
of increased ventricular stiffness, and this in turn causes an increase in LA 
pressure, dimension and function as a result of the increased atrial workload 
during ventricular diastole [188]. In their analysis of over 400 patients, Park et 
al showed that elevated LA pressure is associated with both electro-anatomical 
remodelling of the LA, and AF recurrence after ablation [187]. It therefore 
follows that an increase in left ventricular extracellular volume would be related 
to an increase in LA pressure as seen in our study, and, speculatively, 
incidence and prognosis of AF. 
 
It should be noted that most LV ECV values recorded in this study are not at a 
level usually considered to be pathological, despite the presence of 
hypertension and elevated BMI levels in the cohort (table 6-1). It is possible 
that, given these patients predominantly had paroxysmal AF, that ventricular 
remodelling, if present, was at an early stage. Therefore, this technique may be 
able to identify at an early stage in the disease process those patients at risk of 
AF, or with a lower chance of rhythm control success when AF has been 
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diagnosed. At least one previous study has suggested this, and further 
research is required to explore this concept further [185]. 
 
The other association with LV ECV described in this study is with ICTP levels. 
ICTP is a product of the catabolism of type collagen, the most abundant form 
collagen in the myocardium. Studies examining its predictive value in AF 
ablation are sparse and heterogeneous, but there has been some suggestion 
that it predicts AF recurrence after rhythm control intervention [112, 114]. ICTP 
has not been investigated in conjunction with T1 mapping in AF patients. In 
previous chapters it has been shown that coronary sinus ICTP levels are higher 
than intra-atrial levels in this AF patient cohort, suggesting that the predominant 
site of increased type-I collagen turnover is the ventricle [189]. The T1 mapping 
findings of this study further support this. 
 
Indeed, there was no detectable relationship between atrial fibrosis and ICTP. 
This should be considered when interpreting studies which have examined 
circulating ICTP levels in the context of AF – the association between ICTP and 
AF may predominantly represent ventricular pathology, not only atrial [103, 190, 
191]. This association may warrant further study, particularly to ascertain any 
clinical benefit of using this biomarker in AF recurrence risk stratification, or the 
identification of patients who may benefit from more extensive LA ablation than 
pulmonary vein isolation. 
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6.3.2 Associations with LA LGE 
 
The mechanism outlined above would result in a relationship between atrial and 
ventricular fibrosis. Previously, CMR assessment of fibrosis in AF ablation 
patients has been focussed on the LA over the LV. Marrouche et. al. showed 
that increased LA fibrosis (LA LGE) is associated with a higher likelihood of AF 
recurrence after ablation [98]. This association was shown to be present after 
adjustment for traditional risk factors such as age, sex, and other 
cardiovascular disease. Despite this, the only baseline characteristic in that 
study to show a statistically significant relationship with LA LGE was a history 
of hypertension. Hypertension initially causes a small increase in LV ECV, 
without causing significant LV fibrosis [192]. The association between 
hypertension and LA LGE (and therefore AF recurrence) could therefore also 
be explained in terms of ventricular diastolic dysfunction, as discussed. 
Certainly, the relationship between LA LGE and LA pressure found in this study 
would support this, however the lack of relationship between LA LGE and LA 
pressure seems to stand against such a mechanism. 
 
Although the initial analysis suggested a relationship between LA LGE and LV 
ECV, this was not borne out after multivariable regression, and may have been 
the result of outlying results (fig 6-2). This may suggest that there is no 
relationship between ventricular and atrial fibrosis in these patients, however it 
may also have arisen due to limitations in the imaging modalities used.  The 
pathophysiological mechanisms that lead to left atrial fibrosis measured by LGE 
are not fully understood and histological validation has not been performed. 
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The findings of Marrouche et al. suggest that LA LGE detects fibrosis that is 
relevant to the recurrence of AF, although the mechanism for this remains 
unclear [98]. The hypothesis that LV fibrosis would in turn lead to LA fibrosis is 
not borne out by the findings. This seems counter-intuitive, and further study is 
required to confirm that no such relationship exists. 
 
Left atrial voltage mapping data was used as a surrogate marker of LA fibrosis. 
This measurement, however, revealed no associations with LA LGE. Other 
studies have found low voltage tissue in the LA to be associated with LA LGE, 
and to be an independent predictor of AF recurrence [77, 193]. The reason for 
this discrepancy is not clear, but may be related to the small sample size of this 
study, the possibility that the recruited patients had relatively normal atria, as 
well as the previously discussed limitations of LGE. At best, any evidence for 
such relationships within AF cohorts in either tissue–based or clinical studies is 
currently conflicting (other than in the case of structural heart disease) [32, 34, 
194]. 
 
There was an association between LA LGE and time since diagnosis, a finding 
not seen in previous studies. Caution must be used when interpreting this, as 
this variable was based on a patient-reported date or documentation from 
clinical records, and does not represent a consistent point in the 
pathophysiological progression of AF, from patient to patient. Nevertheless, 
longer duration of AF is a marker of less likelihood of success when pursuing a 
rhythm control strategy, and this finding may reflect the progression of atrial 
fibrosis as the disease progresses – ‘AF begets AF’. This finding, along with 
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the lack of association between LV ECV and LA LGE, and the lack of 
association between LV ECV and duration of AF, also may suggest that the 
process of LA fibrosis is distinct from the process of LV fibrosis in AF patients. 
 
Finally, there was an association of borderline significance between LA LGE 
and gal-3 levels. It has been associated with LV ECV in ischaemic heart 
disease patients, but has not been assessed against LA LGE in AF [194]. It has 
been studied principally in the context of heart failure, but more recently 
attention has turned to AF and its predictive value in AF ablation, with mixed 
results [104, 118, 122]. As gal-3 is a marker of fibrosis, the lower levels in the 
high LA LGE group were unexpected. However, this can be explained when 
other between-group differences are examined; gal-3 has been closely 
associated with BMI previously, and in this study the high LA LGE group had a 
lower mean BMI, which is likely to be a confounding factor. The cohort was too 
small to legitimately apply statistical corrections in the regression analysis, 
which is the likely reason that this association persisted. 
 
6.3.3 PIIINP 
 
PIIINP is a product of the synthesis of type 3 collagen. In this study, PIIINP 
showed no associations with LA or LV measures of fibrosis. This would lend 
support to those studies that have shown no relationship with arrhythmia 
outcome. This lack of association is likely due to the lower volume of type III 
collagen in myocardial tissue, compared to type I, therefore a larger study may 
be required to detect any difference or association. 
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6.3.4 Arrhythmia recurrence 
 
There was no difference in cardiac fibrosis, assessed by any method, between 
the patients who experienced recurrence and those who did not. This study was 
not principally designed to assess this question and so was not powered to do 
so. It should be noted that in the larger study from which this cohort was 
derived, endocardial voltage was the only independent predictor of arrhythmia 
recurrence, suggesting that the technique employed was an accurate 
assessment of LA fibrosis [192]. 
 
6.3.5 Limitations 
 
The main limitation of this study is the small number of participants, and 
therefore the limited power to detect differences between groups. Furthermore, 
while the technique of left atrial gadolinium enhancement is being studied in an 
ever-increasing body of literature, limitations do exist, given the spatial 
resolution of MRI in comparison to the thickness of the atrial myocardium, and 
the lack of standardisation of imaging techniques between studies. 
 
 A clearly defined value for ‘fibrotic’ tissue based on histological validation was 
not used, however the results (particularly the association between ICTP and 
LV ECV) do imply such a relationship exists. It should be noted that isolated 
measurement of LA pressure during an ablation procedure may not reflect 
chronic load status, however repeated or continuous direct LA pressure 
monitoring is not feasible. 
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Nevertheless, the study population is representative of AF ablation patients in 
general and the multiple modality assessment of fibrosis, coupled with the 
measurement of left atrial pressure, is unique and has provided novel insights. 
Indeed, this group represents predominantly paroxysmal AF patients. 
Generally, this represents AF at an earlier stage in its natural history. As such, 
atrial and ventricular remodelling may be less advanced, and further study in 
persistent or permanent AF patients may reinforce these findings. 
 
6.4 Conclusion 
 
LV fibrosis in patients with atrial fibrillation is predominantly associated with LA 
pressure and type 1 collagen turnover, whereas LA fibrosis is associated with 
time since diagnosis. This suggests that different mechanisms may lead to 
fibrosis of the LA and LV in patients with persistent atrial fibrillation, however 
this should be regarded with caution due to the described limitations of the 
study, and further research is required. 
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7 Summary 
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7.1 Overview 
 
The principal objective of this work was to determine the clinical utility of 
circulating biomarkers of fibrosis in the prediction of AF recurrence after rhythm 
control intervention. A literature review was conducted examining the 
pathological effects of fibrosis with regards to atrial fibrillation, in order to 
demonstrate why the assessment of fibrosis should be relevant in AF patients. 
This literature review encompassed not just the pathophysiology of fibrosis in 
AF, but also examined those studies where circulating markers of fibrosis have 
been used to try to predict success of AF ablation and cardioversion. These 
studies were strikingly heterogeneous in terms of patient populations and 
assessment of arrhythmia recurrence. 
 
The review process identified a lack of investigation into the association 
between peripheral levels of such biomarkers and their intra-cardiac levels. As 
described in chapter 3, such investigation is important because fibrosis is not a 
process that is exclusive to the heart, therefore consideration must be given as 
to whether it is cardiac or non-cardiac processes that are being measured in 
the peripheral blood. Compare this with troponin, for example, which is specific 
to the contractile apparatus of the myocyte, and therefore any detectable levels 
above the normal range indicate cardiac pathology. 
 
Furthermore, it identified a lack of investigation into the association between 
such circulating biomarkers and alternative methods for quantification of 
myocardial fibrosis – specifically electrophysiological mapping and CMR. There 
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is no ‘gold standard’ technique for such assessment, however voltage mapping 
appears to be the most consistent method for prediction of arrhythmia 
recurrence. Likewise, the DECAAF study suggested a predictive role for LA 
LGE imaging. If a biomarker were associated with LA fibrosis assessed by 
these methods, it would be likely to have clinical utility. 
 
The project was therefore designed to study a ‘real-world’ population of AF 
patients, using the follow-up duration of 12 months rather than the shorter 
duration of many previous studies. Based on the literature review, 4 biomarkers 
were selected that, based on existing research, held the most promise in this 
application. Two of the biomarkers (PIIINP and ICTP) had been studied on a 
number of previous occasions. Gal-3 had been studied in a more limited 
fashion, but there was a sound pathophysiological basis for supposing it would 
have a predictive role in this context. Finally, FGF-23 had never before been 
studied in this manner, however it was selected based on the review of its 
possible pathophysiological role in AF, and its more well-defined involvement 
in other cardiac pathology (principally heart failure). Thus, there is a spread of 
novelty within the biomarkers with regards to AF. 
 
Finally, the inclusion of CMR offered the novel opportunity to study both atrial 
and ventricular fibrosis, in combination with invasive atrial pressure 
measurement during ablation – thus allowing a mechanistic investigation into 
these processes. 
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7.2 Biomarkers – general points 
 
A striking finding is the level of spread observed in the biomarker results. This 
is an inherent problem when researching blood-based biomarkers. Such 
spread is commonplace and demonstrated in previous studies – the majority of 
those quoted in table 1-1 report large standard deviations or interquartile 
ranges in the biomarker results, particularly in those in which ELISA was used. 
In the work presented in this thesis, biomarker results have been presented as 
individual data plots (figure 3-1). Accordingly, the spread of results is perhaps 
more visually apparent than seen with other methods of presentation, such as 
boxplots. Many studies do not present their biomarker results graphically at all. 
Therefore although the level of spread is high in this study, it is not out of step 
with previous work. Although such spread is not ideal, the statistical methods 
employed in this thesis are standard and designed to elucidate associations in 
data even when there is a large amount of spread. 
 
There are two potential reasons for widely spread results; true spread (i.e. the 
levels are truly widely spread in vivo) or errors associated with the processing 
and assay of blood and serum. In this work, blood was processed consistently 
and according to established practice. Samples were frozen as quickly as 
possible and subjected to only one freeze-thaw cycle. ELISAs were carried out 
in as short a time scale as possible after thawing, to minimise sample 
degradation and inter- and intra-assay variation. As detailed in the methods 
section, co-efficients of variation were well within acceptable limits used in 
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research involving ELISA, albeit this variation is more than would be acceptable 
in clinical diagnosis. Certain steps could have been taken to further improve the 
reliability of the assay; such as running more samples in duplicate or triplicate, 
validation of results and methods with a more experienced operator to human 
error was minimised. 
 
Although the limitations of the assay must be borne in mind, the results suggest 
that there is a true large spread of biomarker levels in the patient population. 
This demonstrates, therefore, that collagen turnover biomarker levels are highly 
variable from patient to patient. The reason for this is likely to lie in the ubiquity 
of extra-cellular matrix throughout the tissues of the body. The selected 
biomarkers were as specific as possible for cardiac tissue, given what has been 
ascertained in previous work (chapter 1).  It is true that type 1 and type 3 
collagens are the most abundant in the myocardium, however they are far from 
exclusive to this tissue and therefore the specificity of serum levels may be less 
than ideal. Similarly, gal-3 and FGF-23 are involved in fibrosis and other 
processes as documented in chapter 1 and this may contribute to the spread 
of results observed. 
 
7.3 Prediction of arrhythmia recurrence 
 
The only predictor of AF recurrence in the ablation group was low voltage on 
electrophysiological mapping, and this is a well-established finding. The novel 
finding that this effect is present when the atrium is mapped in AF has some 
relevance, as voltage information is available to operators in any mapping AF 
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case. If the map has been created in AF, the voltage information would 
conventionally not have been considered relevant, but this may not be the case. 
Nevertheless, the effect demonstrated in this project is not strong enough to 
justify not proceeding with ablation on an individual patient basis, and is not 
practice-altering without further study. 
 
The lack of a predictive effect of LA LGE contrasts with the strong effect found 
in the DECAAF study. As discussed, there are significant methodological 
differences between this study and DECAAF, and along with the small sample 
size this could explain the lack of effect. LA CMR tissue characterisation is still 
in the early stages of development, and further large-scale confirmatory studies 
based on the DECAAF method are awaited. 
 
The lack of predictive effect in most instances with regards to the biomarkers 
may be due to the limitations described – their ubiquity and lack of specificity. 
However, the weak predictive effect of FGF-23 in the context of cardioversion 
warrants further investigation. It should be noted that, subsequent to this work, 
FGF-23 has been found to be predictive of AF incidence. This study appeared 
to be limited by many patients having FGF-23 levels below the detection range 
of the assay – particularly in the ablation cohort – and a more sensitive assay 
may demonstrate a stronger, clinically relevant effect. 
 
7.4 ICTP, LV ECV, and LA pressure 
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ICTP was found to be higher in controls when compared to the ablation cohort. 
Indeed, it was the only biomarker that demonstrated a difference. No such 
difference was found when comparing to the cardioversion cohort, however. 
This may be explained by the higher age and comorbidity in the cardioversion 
cohort with respect to the ablation group – it is possible that the AF-related 
levels of ICTP in the cardioversion patients were masked by non-cardiac 
processes. It is therefore interesting that ICTP was the only biomarker which 
was associated with any of the other markers of cardiac fibrosis – namely LV 
ECV. The elevated LA pressure found in the high LV ECV group adds further 
evidence to a possible mechanistic link between increased ECV (ie increased 
extracellular matrix – one of the hallmarks of fibrosis) and AF. Although this 
conclusion cannot be reached based on the evidence in this study, the results 
provide the basis for possible further work. 
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7.5 Further work 
 
Novel biomarkers become available frequently, as understanding of 
pathological processes progresses. Presently there is no marker that is specific 
to cardiac fibrosis, but if such were identified it should be studied in this context. 
Any future biomarker work should take the findings of this and other studies into 
account when considering the target markers. 
 
MicroRNAs are small, non-coding ribonuclear acids that regulate protein 
synthesis at the post-transcription phase. They were first described in the 
context of cardiovascular disease in 2006 [195]. In plasma, they are protein-
bound or incorporated in vesicles or exosomes, so they are stable and 
measurable by blood sampling. Because of their role in protein synthesis, they 
may be more tissue and process specific than other biomarkers widely studied 
thus far. They have been associated with incidence and prevalence of AF and 
also with specific remodelling of ion channels. Of particular interest in the 
context of this thesis, they have been implicated in the remodelling of the 
extracellular matrix. There is a wide variety of microRNAs currently described, 
and there is hope that an as yet unidentified tissue-specific microRNA may 
serve as a clinically useful biomarker. 
 
With regards to the specific findings in this project, the area with the most 
promise for future study is the association between LV ECV, ICTP, and LA 
pressure. A larger-scale study of AF patients vs. controls may further confirm 
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the association. Such a study could investigate the use of LV ECV as a 
predictor of arrhythmia outcome after AF ablation.  
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The role of circulating markers of fibrosis to predict maintenance 
of sinus rhythm in patients with atrial fibrillation undergoing 
catheter ablation 
Participant information sheet version 3; 11 FEB 2014 (patients 
undergoing AF ablation) 
 
You are being invited to take part in a research study being conducted by the 
Department of Cardiology at Leeds General Infirmary. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with friends, relatives and your GP if you wish.  Ask us if there is anything that is 
not clear, or if you would like more information.  Take time to decide whether or 
not you wish to take part.   
 
Thank you for reading this.  If you decide you do not want to take part in this study 
this will make no difference to the quality of treatment you receive. 
 
WHAT IS THE PURPOSE OF THIS STUDY? 
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We know that atrial fibrillation (AF) causes the heart to under-perform. AF is often 
treated by medication, cardioversion or catheter ablation.  Often this contributes to 
people feeling worse in AF than in normal heart rhythm. However, some patients who 
have undergone ablation go back into AF.  There are limited tests to predict who will 
stay in normal rhythm, and this information is useful in planning further treatment.  
There are changes in the structure of the top chamber of the heart in AF, and we are 
interested in evaluating whether simple blood tests will help in determining what the 
structure of the heart is like and in turn whether ablation will be successful in the long 
term. It is intended that this work will provide real benefits for AF patients in the future. 
As part of the study we will be reviewing your medical records. 
 
WHY HAVE I BEEN CHOSEN? 
This study is designed for patients like yourself who have atrial fibrillation (AF) which 
your doctor (cardiologist) feels is suitable for treatment with  catheter ablation.  You 
have therefore been given this information to read because your doctor thinks you may 
be suitable for this study.  There will be about 90 patients in the study from the Leeds 
area. 
 
DO I HAVE TO TAKE PART? 
It is up to you to decide whether or not you want to take part.  If you decide to take 
part you will be given this information sheet to keep and be asked to sign a consent 
form.  Once you decide to take part you are still free to stop doing the study at any 
time and without giving a reason.  This will not affect the standard of care you receive.   
 
WHAT WILL HAPPEN TO ME IF I DECIDE TAKE PART? 
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Prior to the study, the doctor will do several tests to decide if you are suitable to take 
part. These standard tests are done as a matter of routine on all patients who have 
AF. They will include taking a medical history from you, a physical examination by the 
study doctor, vital signs measurements (heart rate, blood pressure), an ECG 
(electrocardiogram; a test that will read the rate, rhythm and condition of your heart) 
and an Echocardiogram (an ultrasound scan to take pictures of the heart).  In addition 
approximately 60% of the participants will undergo a cardiac magnetic resonance 
imaging scan. This scan will be done on a separate date from the ablation procedure 
at the MRI department. This specialised scan is performed routinely and provides 
useful information to assist the doctor perform your ablation. This specialised scan 
uses a powerful magnet to create detailed images of your heart and detailed 
information about your atria (the chamber that is involved in AF). You will be placed 
on a narrow bed inside the scanner which can cause a small number of patients to 
feel claustrophobic. The scanner can be noisy so we provide headphones to play 
music or the radio to help keep you comfortable and relaxed. 
 
If the results of all the tests show that you are suitable, and if you are willing to take 
part, you can continue with the study. If you decide to take part, we will take blood 
samples from you at the time of the procedure from different parts of the heart that we 
access anyway to perform the procedure. In total we will take approximately 30-40mL 
of blood (3-4 tablespoons). The procedure itself is performed either (i) under local 
anaesthetic and sedation to make you sleepy (although not unconscious) or (ii) under 
general anaesthetic. All patients are kept in hospital overnight for observation following 
their procedure and will usually be discharged the following day. Often, electrical 
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cardioversion is performed to restore normal rhythm during the course of the 
procedure. 
 
WHAT DO I HAVE TO DO? 
For this study, you will have to agree to provide the extra sample of blood during your 
procedure. We will then review your medical records over the course of a year to see 
if you remain in normal rhythm. We may contact either your GP, or yourself by 
telephone. If your AF has not returned after one year, we will need to confirm this with 
a 24 hour recording of your heart rhythm (ECG). You would need to come to hospital 
for an appointment to have the monitor fitted and then drop it off again the next day. 
You would not need to stay in hospital overnight for this test. This test will not be 
necessary if any other test has shown your AF has returned, or if your doctor has 
arranged this separately, as part of your normal follow up.  
We will store the blood samples, and analyse them later.  If new markers become 
available, we will test the stored blood samples again in the future. This does not 
require another blood sample. 
 
 
WHAT ARE THE SIDE EFFECTS OF TAKING PART? 
The blood will be taken at the same time of your procedure and will not involve any 
extra intervention. Echocardiography uses an ultrasound method to image the heart 
with a special microphone and jelly and is generally recognised to be harmless. 
Magnetic resonance imaging uses a powerful magnet to obtain high quality images of 
the heart. A dye called gadolinium is given into a vein in the arm to show up scarred 
areas in the heart. No radiation is involved and the magnetic field is harmless. Metallic 
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objects are not to be taken anywhere near the scanner as they can fly into the magnet 
and can harm people. Please let us know if you have any metal implants or implanted 
devices such as a pacemaker or defibrillator. Gadolinium is not linked to any harmful 
effects in the doses we use for the test. For the catheter ablation procedure we quote 
patients are complication rate of 3%.  The commonest are bleeding due to damage to 
the blood vessels or perforation of the heart requiring emergency drainage. Less 
common are stroke, narrowing of the blood vessels in the heart. Rarely the gullet or 
the nerve that supplies the diaphragm can be damaged. We use xray and x ray dye 
which can rarely cause allergy or kidney damage.  It is important to not that 
participating in the study does not increase your risk of suffering a side effect. 
 
 
WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? 
This study is for research purposes with no immediate benefit to you. However, by 
doing this study you will help to improve our knowledge of the effects of AF on cardiac 
function, helping us better understand how to assess and treat patients with this 
condition.  
 
 
WHAT IF NEW INFORMATION BECOMES AVAILABLE? 
Your study doctor will tell you about any significant new information that becomes 
available during the study that may affect your willingness to continue the trial, and 
you can discuss this with your study doctor. If you decide to stop doing the study, the 
study doctor will make sure you will still be looked after by the doctors as well as you 
would have been if you continued the study.  If you decide to continue you will be 
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asked to sign a new consent form to show that you agree to carry on with the study. It 
may be that if new information becomes known, your study doctor might think it is best 
for you to stop doing the study.  He/she will explain the reasons for this and make sure 
your care continues. 
 
 
WHAT HAPPENS WHEN THE RESEARCH STUDY STOPS? 
At the end of the study, your normal treatment will continue.  
 
 
WHAT IF SOMETHING GOES WRONG?  
If a problem should occur, you should tell Dr. Muzahir Tayebjee immediately at 
Leeds General Infirmary 0113 3926619.  Any necessary treatment will be made 
available by your study doctor(s) at this or another suitable hospital.   
 
Indemnity arrangements have been made in the event of a research patient being 
harmed by Leeds NHS Trust. If you are harmed due to someone’s negligence, then 
you may have grounds for a legal action but you may have to pay for it.  Regardless 
of this, if you wish to complain about any aspect of the way you have been approached 
or treated during the course of this study, the normal National Health Service 
complaints mechanisms will be available to you. In the unlikely event that you have 
any complaints about the way the investigator has carried out the study, you may 
contact the Patient Advisory Liaison service (PALS), Trust Headquarters, St. 
 205 
James’s University Hospital, Beckett Street, Leeds. LS9 7TF: telephone number 
0113 206 6261. 
 
 
WILL MY TAKING PART IN THIS STUDY BE KEPT CONFIDENTIAL? 
Information which is collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will have your 
name and address removed so that you cannot be recognised from it. We will not 
inform your GP about this study as it will make no difference to your usual care. 
 
WHAT WILL HAPPEN WITH THE RESULTS OF THE STUDY? 
The results will be analysed and potentially published in a medical journal. The details 
of how to access the publications will be available through the study doctor. Please 
note you will not be personally identified in any of these reports. 
 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
This research is organised by funds contributed by St Jude Medical and the Leeds 
Electrophysiology Research Fund. 
  
WHO HAS REVIEWED THE STUDY? 
This study has been reviewed by the NRES Committee Yorkshire and the Humber – 
Leeds West. 
 
WHAT IF I HAVE OTHER CONCERNS? 
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If you have any concerns, problems or any questions about this study, you should try 
to contact the study doctor, Dr. Muzahir Tayebjee, Department of Cardiology, 
Leeds General Infirmary, LS1 3EX; Telephone number 0113 3926619 
 
WHAT HAPPENS NOW? 
If you have agreed to take part the study doctor will ask you to sign a consent form. 
Copies of this information sheet and the consent form will be available for you to 
keep. Your study doctor will explain the next step as outlined above. 
 
 
 
 
Thank you for taking the time to read this information sheet. 
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The role of circulating markers of fibrosis to predict 
maintenance of sinus rhythm in patients with atrial fibrillation 
undergoing electrical cardioversion 
Participant information sheet version 2; 22-11-2013 (patients 
undergoing cardioversion) 
 
You are being invited to take part in a research study being conducted by the 
Department of Cardiology at Leeds General Infirmary. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully and discuss it 
with friends, relatives and your GP if you wish.  Ask us if there is anything that is 
not clear, or if you would like more information.  Take time to decide whether or 
not you wish to take part.   
 
Thank you for reading this.  If you decide you do not want to take part in this study 
this will make no difference to the quality of treatment you receive. 
 
WHAT IS THE PURPOSE OF THIS STUDY? 
We know that atrial fibrillation (AF) causes the heart to under-perform. Often this 
contributes to people feeling worse in AF than in normal heart rhythm. However, many 
patients who have electrical cardioversion go back into AF.  There are limited tests to 
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predict who will stay in normal rhythm, and this information is useful in planning further 
treatment.  There are changes in the structure of the top chamber of the heart in AF, 
and we are interested in evaluating whether simple blood tests will help in determining 
what the structure of the heart is like and in turn whether cardioversion will be 
successful in the long term. It is intended that this work will provide real benefits for 
AF patients in the future. As part of the study we will be reviewing your medical 
records. 
 
WHY HAVE I BEEN CHOSEN? 
This study is designed for patients like yourself who have atrial fibrillation (AF) which 
your doctor (cardiologist) feels is suitable for treatment with electrical cardioversion.  
You have therefore been given this information to read because your doctor thinks you 
may be suitable for this study.  There will be about 80 patients in the study from the 
Leeds area. 
 
DO I HAVE TO TAKE PART? 
It is up to you to decide whether or not you want to take part.  If you decide to take 
part you will be given this information sheet to keep and be asked to sign a consent 
form.  Once you decide to take part you are still free to stop doing the study at any 
time and without giving a reason.  This will not affect the standard of care you receive.   
 
WHAT WILL HAPPEN TO ME IF I DECIDE TAKE PART? 
Prior to the study, the doctor will do several tests to decide if you are suitable to take 
part. These standard tests are done as a matter of routine on all patients who have 
AF. They will include taking a medical history from you, a physical examination by the 
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study doctor, vital signs measurements (heart rate, blood pressure), an ECG 
(electrocardiogram; a test that will read the rate, rhythm and condition of your heart) 
and an Echocardiogram (an ultrasound scan to take pictures of the heart). If the results 
of all the tests show that you are suitable, and if you are willing to take part, you can 
continue with the study. If you decide to take part, all that will be required of you is an 
additional sample of blood (10mL or one tablespoon) at the time of blood sampling 
during your pre-assessment visit just before your cardioversion. 
 
WHAT DO I HAVE TO DO? 
For this study, you will have to agree to provide the extra sample of blood. We will then 
review your medical records over the course of a year to see if you remain in normal 
rhythm.  You will not have to attend extra hospital appointments for this, but we may 
contact either your GP, or yourself by telephone. We will store the blood samples, and 
analyse them later.  If new markers become available, we will test the stored blood 
samples again in the future. This does not require another blood sample. 
 
 
WHAT ARE THE SIDE EFFECTS OF TAKING PART? 
The blood will be taken at the same time your routine bloods are taken at the pre-
assessment clinic.  You may experience bruising or mild discomfort as a result of the 
blood test, but this will be required for your normal care anyway. 
 
 
WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? 
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This study is for research purposes with no immediate benefit to you. However, by 
doing this study you will help to improve our knowledge of the effects of AF on cardiac 
function, helping us better understand how to assess and treat patients with this 
condition.  
 
 
WHAT IF NEW INFORMATION BECOMES AVAILABLE? 
Your study doctor will tell you about any significant new information that becomes 
available during the study that may affect your willingness to continue the trial, and 
you can discuss this with your study doctor. If you decide to stop doing the study, the 
study doctor will make sure you will still be looked after by the doctors as well as you 
would have been if you continued the study.  If you decide to continue you will be 
asked to sign a new consent form to show that you agree to carry on with the study. It 
may be that if new information becomes known, your study doctor might think it is best 
for you to stop doing the study.  He/she will explain the reasons for this and make sure 
your care continues. 
 
 
WHAT HAPPENS WHEN THE RESEARCH STUDY STOPS? 
At the end of the study, your normal treatment will continue.  
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WHAT IF SOMETHING GOES WRONG?  
If a problem should occur, you should tell Dr. Muzahir Tayebjee immediately at 
Leeds General Infirmary 0113 3926619.  Any necessary treatment will be made 
available by your study doctor(s) at this or another suitable hospital .   
 
Indemnity arrangements have been made in the event of a research patient being 
harmed by Leeds NHS Trust. If you are harmed due to someone’s negligence, then 
you may have grounds for a legal action but you may have to pay for it.  Regardless 
of this, if you wish to complain about any aspect of the way you have been approached 
or treated during the course of this study, the normal National Health Service 
complaints mechanisms will be available to you. In the unlikely event that you have 
any complaints about the way the investigator has carried out the study, you may 
contact the Patient Advisory Liaison service (PALS), Trust Headquarters, St. 
James’s University Hospital, Beckett Street, Leeds. LS9 7TF: telephone number 
0113 206 6261. 
 
 
WILL MY TAKING PART IN THIS STUDY BE KEPT CONFIDENTIAL? 
Information which is collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will have your 
name and address removed so that you cannot be recognised from it. We will not 
inform your GP about this study as it will make no difference to your usual care. 
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WHAT WILL HAPPEN WITH THE RESULTS OF THE STUDY? 
The results will be analysed and potentially published in a medical journal. The details 
of how to access the publications will be available through the study doctor. Please 
note you will not be personally identified in any of these reports. 
 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
This research is organised by funds contributed by St Jude Medical and the Leeds 
Electrophysiology Research Fund. 
  
WHO HAS REVIEWED THE STUDY? 
This study has been reviewed by the NRES Committee Yorkshire and the Humber – 
Leeds West. 
 
WHAT IF I HAVE OTHER CONCERNS? 
If you have any concerns, problems or any questions about this study, you should try 
to contact the study doctor, Dr. Muzahir Tayebjee, Department of Cardiology, 
Leeds General Infirmary, LS1 3EX; Telephone number 0113 3926619 
 
WHAT HAPPENS NOW? 
If you have agreed to take part the study doctor will ask you to sign a consent form. 
Copies of this information sheet and the consent form will be available for you to 
keep. Your study doctor will explain the next step as outlined above. 
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Thank you for taking the time to read this information sheet. 
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The role of circulating markers of fibrosis to predict maintenance 
of sinus rhythm in patients with atrial fibrillation undergoing 
electrical cardioversion 
Participant information sheet version 2; 22-11-2013 (control 
patients for cardioversion study) 
 
You are being invited to take part in a research study being conducted by the 
Department of Cardiology at Leeds General Infirmary. Before you decide it is 
important for you to understand why the research is being done and what it will  
involve.  Please take time to read the following information carefully and discuss it 
with friends, relatives and your GP if you wish.  Ask us if there is anything that is 
not clear, or if you would like more information.  Take time to decide whether or 
not you wish to take part.   
 
Thank you for reading this.  If you decide you do not want to take part in this study 
this will make no difference to the quality of treatment you receive. 
 
WHAT IS THE PURPOSE OF THIS STUDY? 
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We know that atrial fibrillation (AF) causes the heart to under-perform. Often this 
contributes to people feeling worse in AF than in normal heart rhythm. However, many 
patients who have electrical cardioversion go back into AF.  There are limited tests to 
predict who will stay in normal rhythm, and this information is useful in planning further 
treatment.  There are changes in the structure of the top chamber of the heart in AF, 
and we are interested in evaluating whether simple blood tests will help in determining 
what the structure of the heart is like and in turn whether cardioversion will be 
successful in the long term. It is intended that this work will provide real benefits for 
AF patients in the future. As part of the study we will be reviewing your medical 
records. 
 
WHY HAVE I BEEN CHOSEN? 
Atrial fibrillation (AF) is the commonest cause of heart rhythm disorders. We are 
interested in studying certain compounds in blood that may give us information about 
the health of the heart chamber that is responsible for AF. In order to analyse the 
significance of the research markers, we need to compare them to individuals that do 
not have AF. This study is designed for patients like yourself who do not have AF but 
match patients that we have in our study for other medical conditions, age and gender.  
You have therefore been given this information to read because your doctor thinks you 
may be suitable for this study. 
 
DO I HAVE TO TAKE PART? 
It is up to you to decide whether or not you want to take part.  If you decide to take 
part you will be given this information sheet to keep and be asked to sign a consent 
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form.  Once you decide to take part you are still free to stop doing the study at any 
time and without giving a reason.  This will not affect the standard of care you receive.   
 
WHAT WILL HAPPEN TO ME IF I DECIDE TAKE PART? 
Prior to the study, the doctor will do several tests to decide if you are suitable to take 
part. These standard tests are done as a matter of routine on all patients with 
cardiovascular conditions. They may include taking a medical history from you, a 
physical examination by the study doctor, vital signs measurements (heart rate, blood 
pressure), an ECG (electrocardiogram; a test that will read the rate, rhythm and 
condition of your heart) and an Echocardiogram (an ultrasound scan to take pictures 
of the heart). If the results of all the tests show that you are suitable, and if you are 
willing to take part, you can continue with the study. If you decide to take part, all that 
will be required of you is an additional sample of blood (10mL or one tablespoon). 
 
WHAT DO I HAVE TO DO? 
For this study, you will have to agree to provide the extra sample of blood. We will then 
compare the results of your blood tests with patients who have AF.  You will not have 
to attend extra hospital appointments for this. We will store the blood samples, and 
analyse them later.  If new markers become available, we will test the stored blood 
samples again in the future. This does not require another blood sample. 
 
WHAT ARE THE SIDE EFFECTS OF TAKING PART? 
The blood will be taken at the same time your routine bloods are taken at the pre-
assessment clinic.  You may experience bruising or mild discomfort as a result of the 
blood test, but this may be required for your normal care anyway. 
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WHAT ARE THE POSSIBLE BENEFITS OF TAKING PART? 
This study is for research purposes with no immediate benefit to you. However, by 
doing this study you will help to improve our knowledge of the effects of AF on cardiac 
function, helping us better understand how to assess and treat patients with this 
condition.  
 
 
WHAT IF NEW INFORMATION BECOMES AVAILABLE? 
Your study doctor will tell you about any significant new information that becomes 
available during the study that may affect your willingness to continue the trial, and 
you can discuss this with your study doctor. If you decide to stop doing the study, the 
study doctor will make sure you will still be looked after by the doctors as well as you 
would have been if you continued the study.  If you decide to continue you will be 
asked to sign a new consent form to show that you agree to carry on with the study. It 
may be that if new information becomes known, your study doctor might think it is best 
for you to stop doing the study.  He/she will explain the reasons for this and make sure 
your care continues. 
 
 
WHAT HAPPENS WHEN THE RESEARCH STUDY STOPS? 
At the end of the study, your normal treatment will continue.  
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WHAT IF SOMETHING GOES WRONG?  
If a problem should occur, you should tell Dr. Muzahir Tayebjee immediately at 
Leeds General Infirmary 0113 3926619.  Any necessary treatment will be made 
available by your study doctor(s) at this or another suitable hospital .   
 
Indemnity arrangements have been made in the event of a research patient being 
harmed by Leeds NHS Trust. If you are harmed due to someone’s negligence, then 
you may have grounds for a legal action but you may have to pay for it.  Regardless 
of this, if you wish to complain about any aspect of the way you have been approached 
or treated during the course of this study, the normal National Health Service 
complaints mechanisms will be available to you. In the unlikely event that you have 
any complaints about the way the investigator has carried out the study, you may 
contact the Patient Advisory Liaison service (PALS), Trust Headquarters, St. 
James’s University Hospital, Beckett Street, Leeds. LS9 7TF: telephone number 
0113 206 6261. 
 
 
WILL MY TAKING PART IN THIS STUDY BE KEPT CONFIDENTIAL? 
Information which is collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will have your 
name and address removed so that you cannot be recognised from it. We will not 
inform your GP about this study as it will make no difference to your usual care. 
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WHAT WILL HAPPEN WITH THE RESULTS OF THE STUDY? 
The results will be analysed and potentially published in a medical journal. The details 
of how to access the publications will be available through the study doctor. Please 
note you will not be personally identified in any of these reports. 
 
WHO IS ORGANISING AND FUNDING THE RESEARCH? 
This research is organised by funds contributed by St Jude Medical and the Leeds 
Electrophysiology Research Fund. 
  
WHO HAS REVIEWED THE STUDY? 
This study has been reviewed by the NRES Committee Yorkshire and the Humber – 
Leeds West. 
 
WHAT IF I HAVE OTHER CONCERNS? 
If you have any concerns, problems or any questions about this study, you should try 
to contact the study doctor, Dr. Muzahir Tayebjee, Department of Cardiology, 
Leeds General Infirmary, LS1 3EX; Telephone number 0113 3926619 
 
WHAT HAPPENS NOW? 
If you have agreed to take part the study doctor will ask you to sign a consent form. 
Copies of this information sheet and the consent form will be available for you to 
keep. Your study doctor will explain the next step as outlined above. 
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Thank you for taking the time to read this information sheet. 
 
 
 
